1
|
Kaiser S, Verboket RD, Frank J, Marzi I, Janko M. Effectiveness of combined local therapy with antibiotics and fibrin vs. vacuum-assisted wound therapy in soft tissue infections: a retrospective study. Eur J Trauma Emerg Surg 2024:10.1007/s00068-024-02483-1. [PMID: 38466400 DOI: 10.1007/s00068-024-02483-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2024] [Accepted: 02/20/2024] [Indexed: 03/13/2024]
Abstract
PURPOSE Soft tissue infections can be severe and life-threatening. Their treatment consists currently in radical surgical wound debridement and combined systemic antimicrobial therapy. Different side effects are possible. Local antibiotic therapy represents a new approach to reduce side effects and improve healing. The aim of this study is to assess the effectiveness of the local sprayed use of antibiotics with fibrin sealing compared with negative pressure wound therapy as an established treatment of soft-tissue infections. METHODS In this retrospective study, patients with soft tissue infections who underwent surgical treatment were analysed. One group consists of patients, who received local fibrin-antibiotic spray (FAS) (n = 62). Patients treated by vacuum-assisted wound therapy (VAWT) as the established treatment were the control group (n = 57). Main outcomes were differences in the success of healing, the duration until healing and the number of needed operations. RESULTS Clinical healing could be achieved for 55 patients (98.21%) in the FAS group vs. 47 patients (92.16%) in the VAWT group (p = 0.19). Time to require this was 10.65 ± 10.38 days in the FAS group and 22.85 ± 14.02 days in the VAWT group (p < 0.001). In the FAS group, patients underwent an average of 1.44 ± 0.72 vs.3.46 ± 1.66 operations in the VAWT group (p < 0.001). CONCLUSION Compared to vacuum-assisted wound therapy in soft tissue infections, local fibrin-antibiotic spray shows faster clinical healing and less needed operations. Leading to shorter hospital stays and more satisfied patients. The combination of sprayed fibrin and antibiotics can be seen as a promising and effective method.
Collapse
Affiliation(s)
- S Kaiser
- Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor‑Stern‑Kai 7, 60590, Frankfurt am Main, Germany
| | - R D Verboket
- Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor‑Stern‑Kai 7, 60590, Frankfurt am Main, Germany.
| | - J Frank
- Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor‑Stern‑Kai 7, 60590, Frankfurt am Main, Germany
| | - I Marzi
- Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor‑Stern‑Kai 7, 60590, Frankfurt am Main, Germany
| | - M Janko
- Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor‑Stern‑Kai 7, 60590, Frankfurt am Main, Germany
| |
Collapse
|
2
|
Michels S, Massutí B, Vasyliv I, Stratmann J, Frank J, Adams A, Felip E, Grohé C, Rodriguez-Abreu D, Bischoff H, Carcereny I Costa E, Corral J, Pereira E, Fassunke J, Fischer RN, Insa A, Koleczko S, Nogova L, Reck M, Reutter T, Riedel R, Schaufler D, Scheffler M, Weisthoff M, Provencio M, Merkelbach-Bruse S, Hellmich M, Sebastian M, Büttner R, Persigehl T, Rosell R, Wolf J. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial. ESMO Open 2024; 9:102237. [PMID: 38350336 PMCID: PMC10937203 DOI: 10.1016/j.esmoop.2024.102237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 12/12/2023] [Accepted: 01/07/2024] [Indexed: 02/15/2024] Open
Abstract
BACKGROUND In 2019, we reported the first efficacy and safety analysis of EUCROSS, a phase II trial investigating crizotinib in ROS1 fusion-positive lung cancer. At that time, overall survival (OS) was immature and the effect of crizotinib on intracranial disease control remained unclear. Here, we present the final analysis of OS, systemic and intracranial activity, and the impact of co-occurring aberrations. MATERIALS AND METHODS EUCROSS was a prospective, single-arm, phase II trial. The primary endpoint was best overall response rate (ORR) using RECIST 1.1. Secondary and exploratory endpoints were progression-free survival (PFS), OS, and efficacy in pre-defined subgroups. RESULTS Median OS of the intention-to-treat population (N = 34) was 54.8 months [95% confidence interval (CI) 20.3 months-not reached (NR); median follow-up 81.4 months] and median all-cause PFS of the response-evaluable population (N = 30) was 19.4 months (95% CI 10.1-32.2 months). Time on treatment was significantly correlated with OS (R = 0.82; P < 0.0001). Patients with co-occurring TP53 aberrations (28%) had a significantly shorter OS [hazard ratio (HR) 11; 95% CI 2.0-56.0; P = 0.006] and all-cause PFS (HR 4.2; 95% CI 1.2-15; P = 0.025). Patients with central nervous system (CNS) involvement at baseline (N = 6; 20%) had a numerically shorter median OS and all-cause PFS. Median intracranial PFS was 32.2 months (95% CI 23.7 months-NR) and the rate of isolated CNS progression was 24%. CONCLUSIONS Our final analysis proves the efficacy of crizotinib in ROS1-positive lung cancer, but also highlights the devastating impact of TP53 mutations on survival and treatment efficacy. Additionally, our data show that CNS disease control is durable and the risk of CNS progression while on crizotinib treatment is low.
Collapse
Affiliation(s)
- S Michels
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany.
| | - B Massutí
- Department for Oncology, Alicante University Hospital-ISABIAL, Alicante, Spain
| | - I Vasyliv
- University of Cologne, Faculty of Medicine and University Hospital of Colone, Department of Radiology and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany
| | - J Stratmann
- Department of Hematology and Oncology, University Hospital of Frankfurt, Frankfurt am Main
| | - J Frank
- Faculty of Medicine and University Hospital of Cologne, Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany
| | - A Adams
- Faculty of Medicine and University Hospital of Cologne, Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany
| | - E Felip
- Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - C Grohé
- Department of Respiratory Medicine, ELK Berlin, Berlin, Germany
| | - D Rodriguez-Abreu
- Universidad de Las Palmas de Gran Canaria, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Gran Canaria, Spain
| | - H Bischoff
- Thoraxonkologie, Thoraxklinik, Heidelberg, Germany
| | - E Carcereny I Costa
- Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona and Badalona-Applied Research Group in Oncology (B-ARGO), Badalona
| | - J Corral
- Department for Medical Oncology, Clínica Universidad de Navarra, Madrid
| | - E Pereira
- Spanish Lung Cancer Group, Barcelona, Spain
| | - J Fassunke
- University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany
| | - R N Fischer
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany
| | - A Insa
- Hospital Clínico Universitario de Valencia, València, Spain
| | - S Koleczko
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany
| | - L Nogova
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany
| | - M Reck
- Department for Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research, Großhansdorf
| | - T Reutter
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany; Department of Oncology, Asklepios Clinic Altona, Hematology, Palliative Care and Rheumatology, Asklepios Tumorzentrum Hamburg, Hamburg, Germany
| | - R Riedel
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany
| | - D Schaufler
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany
| | - M Scheffler
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany
| | - M Weisthoff
- University of Cologne, Faculty of Medicine and University Hospital of Colone, Department of Radiology and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany
| | - M Provencio
- Department of Medical Oncology, Hospital Universitario Puerta de Hierro de Majadahonda, Madrid
| | - S Merkelbach-Bruse
- University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany
| | - M Hellmich
- Faculty of Medicine and University Hospital of Cologne, Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany
| | - M Sebastian
- Department of Hematology and Oncology, University Hospital of Frankfurt, Frankfurt am Main
| | - R Büttner
- University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany
| | - T Persigehl
- University of Cologne, Faculty of Medicine and University Hospital of Colone, Department of Radiology and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany
| | - R Rosell
- Germans Trias i Pujol Research Institute (IGTP), Badalona; Quiron Dexeus University Hospital, Institute of Oncology Rosell (IOR), Barcelona, Spain
| | - J Wolf
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany
| |
Collapse
|
3
|
Langguth P, Wolf C, Sedaghat S, Huhndorf M, Frank J, Both M, Jansen O, Salehi Ravesh M, Lebenatus A. Clinical Value of Using Heart Rate Variability Biofeedback Before Elective CT Coronary Angiography to Reduce Heart Rate and the Need for Beta-Blockers. Appl Psychophysiol Biofeedback 2023; 48:393-401. [PMID: 37341838 PMCID: PMC10581922 DOI: 10.1007/s10484-023-09590-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/10/2023] [Indexed: 06/22/2023]
Abstract
The value of biofeedback before elective coronary computed tomography angiography (CCTA) to reduce patients' heart rates (HR) was investigated in the current work. Sixty patients who received CCTA to exclude coronary artery disease were included in our study and separated into two groups: with biofeedback (W-BF) and without biofeedback (WO-BF). The W-BF group used a biofeedback device for 15 min before CCTA. HR was determined in each patient at four measurement time points (MTP): during the pre-examination interview (MTP1), positioning on the CT patient table before CCTA (MTP2), during CCTA image acquisition (MTP3), and after completing CCTA (MTP4). If necessary, beta-blockers were administered in both groups after MTP2 until a HR of less than 65 bpm was achieved. Two board-certified radiologists subsequently assessed the image quality and analyzed the findings. Overall, the need for beta-blockers was significantly lower in patients in the W-BF group than the WO-BF group (p = 0.032). In patients with a HR of 81-90, beta-blockers were not required in four of six cases in the W-BF group, whereas in the WO-BF group all patients needed beta-blockers (p = 0.03). The amount of HR reduction between MTP1 and MTP2 was significantly higher in the W-BF compared to the WO-BF group (p = 0.028). There was no significant difference between the W-BF and WO-BF groups regarding image quality (p = 0.179). By using biofeedback prior to elective CCTA, beta-blocker use could be decreased without compromising CT image quality and analysis, especially in patients with an initial HR of 81-90 bpm.
Collapse
Affiliation(s)
- Patrick Langguth
- Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
| | - Carmen Wolf
- Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Sam Sedaghat
- Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
| | - Monika Huhndorf
- Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Johanne Frank
- Department for Internal Medicine III, Molecular Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Marcus Both
- Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Olav Jansen
- Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Mona Salehi Ravesh
- Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Annett Lebenatus
- Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| |
Collapse
|
4
|
Langguth P, Wolf C, Sedaghat S, Huhndorf M, Frank J, Both M, Jansen O, Salehi Ravesh M, Lebenatus A. Correction to: Clinical Value of Using Heart Rate Variability Biofeedback Before Elective CT Coronary Angiography to Reduce Heart Rate and the Need for BetaBlockers. Appl Psychophysiol Biofeedback 2023; 48:403. [PMID: 37428434 PMCID: PMC10581941 DOI: 10.1007/s10484-023-09596-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/11/2023]
Affiliation(s)
- Patrick Langguth
- Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
| | - Carmen Wolf
- Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Sam Sedaghat
- Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
| | - Monika Huhndorf
- Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Johanne Frank
- Department for Internal Medicine III, Molecular Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Marcus Both
- Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Olav Jansen
- Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Mona Salehi Ravesh
- Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Annett Lebenatus
- Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| |
Collapse
|
5
|
Wundram S, Seoudy H, Dümmler JC, Ritter L, Frank J, Puehler T, Lutter G, Lutz M, Saad M, Bramlage P, Sathananthan J, Wood DA, Lauck SB, Frey N, Frank D. Is the outcome of elective vs non-elective patients undergoing transcatheter aortic valve implantation different? Results of a single-centre, observational assessment of outcomes at a large university clinic. BMC Cardiovasc Disord 2023; 23:295. [PMID: 37301870 PMCID: PMC10257817 DOI: 10.1186/s12872-023-03317-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Accepted: 05/22/2023] [Indexed: 06/12/2023] Open
Abstract
BACKGROUND Transcatheter aortic valve implantation (TAVI) can either be conducted as an elective (scheduled in advance) or a non-elective procedure performed during an unplanned hospital admission. The objective of this study was to compare the outcomes of elective and non-elective TAVI patients. METHODS This single-centre study included 512 patients undergoing transfemoral TAVI between October 2018 and December 2020; 378 (73.8%) were admitted for elective TAVI, 134 (26.2%) underwent a non-elective procedure. Our TAVI programme entails an optimized fast-track concept aimed at minimizing the total length of stay to ≤ 5 days for elective patients which in the German healthcare system is currently defined as the minimal time period to safely perform TAVI. Clinical characteristics and survival rates at 30 days and 1 year were analysed. RESULTS Patients who underwent non-elective TAVI had a significantly higher comorbidity burden. Median duration from admission to discharge was 6 days (elective group 6 days versus non-elective group 15 days; p < 0.001), including a median postprocedural stay of 5 days (elective 4 days versus non-elective 7 days; p < 0.001). All-cause mortality at 30 days was 1.1% for the elective group and 3.7% for non-elective patients (p = 0.030). At 1 year, all-cause mortality among elective TAVI patients was disproportionately lower than in non-elective patients (5.0% versus 18.7%, p < 0.001). In the elective group, 54.5% of patients could not be discharged early due to comorbidities or procedural complications. Factors associated with a failure of achieving a total length of stay of ≤ 5 days comprised frailty syndrome, renal impairment as well as new permanent pacemaker implantation, new bundle branch block or atrial fibrillation, life-threatening bleeding, and the use of self-expanding valves. After multivariate adjustment, new permanent pacemaker implantation (odds ratio 6.44; 95% CI 2.59-16.00), life-threatening bleeding (odds ratio 4.19; 95% confidence interval 1.82-9.66) and frailty syndrome (odds ratio 5.15; 95% confidence interval 2.40-11.09; all p < 0.001, respectively) were confirmed as significant factors. CONCLUSIONS While non-elective patients had acceptable periprocedural outcomes, mortality rates at 1 year were significantly higher compared to elective patients. Approximately only half of elective patients could be discharged early. Improvements in periprocedural care, follow-up strategies and optimized treatment of both elective and non-elective TAVI patients are needed.
Collapse
Affiliation(s)
- Steffen Wundram
- Department of Internal Medicine III, Cardiology, Angiology and Critical Care, University Hospital Schleswig-Holstein, Arnold-Heller-Str.3, Haus K3, 24105 Kiel, Germany
| | - Hatim Seoudy
- Department of Internal Medicine III, Cardiology, Angiology and Critical Care, University Hospital Schleswig-Holstein, Arnold-Heller-Str.3, Haus K3, 24105 Kiel, Germany
- DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany
| | - Johannes C. Dümmler
- Department of Anaesthesiology and Intensive Care Medicine, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Lukas Ritter
- Department of Internal Medicine III, Cardiology, Angiology and Critical Care, University Hospital Schleswig-Holstein, Arnold-Heller-Str.3, Haus K3, 24105 Kiel, Germany
| | - Johanne Frank
- Department of Internal Medicine III, Cardiology, Angiology and Critical Care, University Hospital Schleswig-Holstein, Arnold-Heller-Str.3, Haus K3, 24105 Kiel, Germany
- DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany
| | - Thomas Puehler
- DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany
- Department of Cardiac and Vascular Surgery, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Georg Lutter
- DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany
- Department of Cardiac and Vascular Surgery, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Matthias Lutz
- Department of Internal Medicine III, Cardiology, Angiology and Critical Care, University Hospital Schleswig-Holstein, Arnold-Heller-Str.3, Haus K3, 24105 Kiel, Germany
- DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany
| | - Mohammed Saad
- Department of Internal Medicine III, Cardiology, Angiology and Critical Care, University Hospital Schleswig-Holstein, Arnold-Heller-Str.3, Haus K3, 24105 Kiel, Germany
| | - Peter Bramlage
- Institute for Pharmacology and Preventive Medicine, Bahnhofstrasse 20, 49661 Cloppenburg, Germany
| | - Janarthanan Sathananthan
- Centre for Cardiovascular Innovation – Centre d’Innovation Cardiovasculaire, St Paul’s and Vancouver General Hospitals, University of British Columbia, Vancouver, Canada
| | - David A. Wood
- Centre for Cardiovascular Innovation – Centre d’Innovation Cardiovasculaire, St Paul’s and Vancouver General Hospitals, University of British Columbia, Vancouver, Canada
| | - Sandra B. Lauck
- Centre for Cardiovascular Innovation – Centre d’Innovation Cardiovasculaire, St Paul’s and Vancouver General Hospitals, University of British Columbia, Vancouver, Canada
- School of Nursing, University of British Columbia, Vancouver, Canada
| | - Norbert Frey
- University Hospital of Heidelberg, Cardiology, , Heidelberg, Germany
- DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg, Germany
| | - Derk Frank
- Department of Internal Medicine III, Cardiology, Angiology and Critical Care, University Hospital Schleswig-Holstein, Arnold-Heller-Str.3, Haus K3, 24105 Kiel, Germany
- DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany
| |
Collapse
|
6
|
Foo JC, Redler S, Forstner AJ, Basmanav FB, Pethukova L, Guo J, Streit F, Witt SH, Sirignano L, Zillich L, Avasthi S, Ripke S, Christiano AM, Tesch F, Schmitt J, Nöthen MM, Betz RC, Rietschel M, Frank J. Exploring the overlap between alopecia areata and major depressive disorder: Epidemiological and genetic perspectives. J Eur Acad Dermatol Venereol 2023. [PMID: 36695075 DOI: 10.1111/jdv.18921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Accepted: 01/05/2023] [Indexed: 01/26/2023]
Abstract
BACKGROUND Research suggests that Alopecia areata (AA) and Major Depressive Disorder (MDD) show substantial comorbidity. To date, no study has investigated the hypothesis that this is attributable to shared genetic aetiology. OBJECTIVES To investigate AA-MDD comorbidity on the epidemiological and molecular genetic levels. METHODS First, epidemiological analyses were performed using data from a cohort of adult German health insurance beneficiaries (n = 1.855 million) to determine the population-based prevalence of AA-MDD comorbidity. Second, analyses were performed to determine the prevalence of MDD in a clinical AA case-control sample with data on psychiatric phenotypes, stratifying for demographic factors to identify possible contributing factors to AA-MDD comorbidity. Third, the genetic overlap between AA and MDD was investigated using a polygenic risk score (PRS) approach and linkage disequilibrium score (LDSC) regression. For PRS, summary statistics from a large MDD GWAS meta-analysis (PGC-MD2) were used as the training sample, while a Central European AA cohort, including the above-mentioned AA patients, and an independent replication US-AA cohort were used as target samples. LDSC was performed using summary statistics of PGC-MD2 and the largest AA meta-analysis to date. RESULTS High levels of AA-MDD comorbidity were reported in the population-based (MDD in 24% of AA patients), and clinical samples (MDD in 44% of AA patients). MDD-PRS explained a modest proportion of variance in AA case-control status (R2 = 1%). This signal was limited to the major histocompatibility complex (MHC) region on chromosome 6. LDSC regression (excluding MHC) revealed no significant genetic correlation between AA and MDD. CONCLUSIONS As in previous research, AA patients showed an increased prevalence of MDD. The present analyses suggest that genetic overlap may be confined to the MHC region, which is implicated in immune function. More detailed investigation is required to refine understanding of how the MHC is involved in the development of AA and MDD comorbidity.
Collapse
Affiliation(s)
- J C Foo
- Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - S Redler
- Institute of Human Genetics, Medical Faculty & University Hospital Bonn, University of Bonn, Bonn, Germany.,Institute of Human Genetics, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - A J Forstner
- Institute of Human Genetics, Medical Faculty & University Hospital Bonn, University of Bonn, Bonn, Germany.,Institute of Neuroscience and Medicine (INM-1), Research Center Jülich, Jülich, Germany
| | - F B Basmanav
- Institute of Human Genetics, Medical Faculty & University Hospital Bonn, University of Bonn, Bonn, Germany
| | - L Pethukova
- Department of Dermatology, Columbia University, New York City, New York, USA.,Department of Epidemiology, Columbia University, New York City, New York, USA
| | - J Guo
- Department of Biostatistics, Columbia University, New York City, New York, USA
| | - F Streit
- Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - S H Witt
- Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - L Sirignano
- Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - L Zillich
- Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - S Avasthi
- Laboratory for Statistical Genetics, Charité University Hospital Berlin, Berlin, Germany
| | - S Ripke
- Laboratory for Statistical Genetics, Charité University Hospital Berlin, Berlin, Germany
| | - A M Christiano
- Department of Genetics and Development, Columbia University, New York City, New York, USA
| | - F Tesch
- Center for Evidence-Based Healthcare, University Hospital Carl Gustav Carus and Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, Dresden, Germany
| | - J Schmitt
- Center for Evidence-Based Healthcare, University Hospital Carl Gustav Carus and Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, Dresden, Germany
| | - M M Nöthen
- Institute of Human Genetics, Medical Faculty & University Hospital Bonn, University of Bonn, Bonn, Germany
| | - R C Betz
- Institute of Human Genetics, Medical Faculty & University Hospital Bonn, University of Bonn, Bonn, Germany
| | - M Rietschel
- Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - J Frank
- Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| |
Collapse
|
7
|
Knott E, Zlevor A, Hinshaw L, Laeseke P, Longhurst C, Frank J, Bradley C, Couillard A, Xu Z, Lee F, Ziemlewicz T. Abstract No. 170 Histotripsy vs. microwave ablation in the liver: a comparison study in a porcine model. J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
8
|
Seoudy H, Shamekhi J, Voigtländer L, Ludwig S, Frank J, Kujat T, Bramlage P, Al-Kassou B, Sugiura A, Rangrez AY, Schofer N, Puehler T, Lutter G, Seiffert M, Nickenig G, Conradi L, Frey N, Westermann D, Sinning JM, Frank D. C-Reactive Protein to Albumin Ratio in Patients Undergoing Transcatheter Aortic Valve Replacement. Mayo Clin Proc 2022; 97:931-940. [PMID: 35410750 DOI: 10.1016/j.mayocp.2021.11.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Revised: 10/11/2021] [Accepted: 11/03/2021] [Indexed: 12/20/2022]
Abstract
OBJECTIVE To evaluate whether the serum C-reactive protein to albumin ratio (CAR) could be used for risk stratification of patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS). PATIENTS AND METHODS Frailty is a predictor of poor outcomes in patients undergoing AS interventions. The CAR reflects key components of frailty (systemic inflammation and nutrition) and could potentially be implemented into assessment and management strategies for patients with AS. From March 1, 2010, through February 29, 2020, 1836 patients were prospectively enrolled in an observational TAVR database. Patients (prospective development cohort, n=763) were grouped into CAR quartiles to compare the upper quartile (CAR Q4) with the lower quartiles (CAR Q1-3). Primary end point was all-cause mortality. Results were verified in an independent retrospective cohort (n=1403). RESULTS The CAR Q4 had a higher prevalence of impaired left ventricular function, atrial fibrillation, diabetes, and cerebrovascular disease and a higher median logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) vs CAR Q1-3. After median follow-up of 15.0 months, all-cause mortality was significantly higher in CAR Q4 vs CAR Q1-3 (P<.001). In multivariable analyses, risk factors for all-cause mortality were CAR Q4 (>0.1632; hazard ratio, 1.45; 95% confidence interval, 1.05 to 2.00; P=.03), N-terminal pro-B-type natriuretic peptide Q4 (>3230 pg/mL [to convert to ng/L, multiply by 1), high-sensitivity troponin T Q4 (>0.0395 ng/mL [to convert to μg/L, multiply by 1]), above-median logistic EuroSCORE (16.1%), myocardial infarction, Acute Kidney Injury Network stage 3, and life-threatening bleeding. CONCLUSION Elevated CAR was associated with increased risk of all-cause mortality in patients undergoing transfemoral TAVR. The CAR, a simple, objective tool to assess frailty, could be incorporated into assessing patients with AS being considered for TAVR.
Collapse
Affiliation(s)
- Hatim Seoudy
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg, Kiel, Lübeck, Germany
| | - Jasmin Shamekhi
- Department of Medicine II, Heart Center Bonn, University Hospital Bonn, Bonn, Germany
| | - Lisa Voigtländer
- Department of General and Interventional Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg, Kiel, Lübeck, Germany
| | - Sebastian Ludwig
- Department of General and Interventional Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg, Kiel, Lübeck, Germany
| | - Johanne Frank
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg, Kiel, Lübeck, Germany
| | - Tim Kujat
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Peter Bramlage
- Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany
| | - Baravan Al-Kassou
- Department of Medicine II, Heart Center Bonn, University Hospital Bonn, Bonn, Germany
| | - Atsushi Sugiura
- Department of Medicine II, Heart Center Bonn, University Hospital Bonn, Bonn, Germany
| | - Ashraf Yusuf Rangrez
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg, Kiel, Lübeck, Germany
| | - Niklas Schofer
- Department of General and Interventional Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany
| | - Thomas Puehler
- Department of Cardiac and Vascular Surgery, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg, Kiel, Lübeck, Germany
| | - Georg Lutter
- Department of Cardiac and Vascular Surgery, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg, Kiel, Lübeck, Germany
| | - Moritz Seiffert
- Department of General and Interventional Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg, Kiel, Lübeck, Germany
| | - Georg Nickenig
- Department of Medicine II, Heart Center Bonn, University Hospital Bonn, Bonn, Germany
| | - Lenard Conradi
- Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany
| | - Norbert Frey
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg, Kiel, Lübeck, Germany
| | - Dirk Westermann
- Department of General and Interventional Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg, Kiel, Lübeck, Germany
| | - Jan-Malte Sinning
- Department of Medicine II, Heart Center Bonn, University Hospital Bonn, Bonn, Germany
| | - Derk Frank
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg, Kiel, Lübeck, Germany.
| |
Collapse
|
9
|
Keller M, Kreuzer M, Reidy B, Scheurer A, Guggenbühl B, Luder M, Frank J, Giller K. Effects on performance, carcass and meat quality of replacing maize silage and concentrate by grass silage and corn-cob mix in the diet of growing bulls. Meat Sci 2022; 188:108795. [DOI: 10.1016/j.meatsci.2022.108795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2022] [Revised: 02/18/2022] [Accepted: 03/02/2022] [Indexed: 10/18/2022]
|
10
|
Seoudy H, Eberstein M, Frank J, Thomann M, Puehler T, Lutter G, Lutz M, Bramlage P, Frey N, Saad M, Frank D. HFA‐PEFF score: prognosis in patients with preserved ejection fraction after transcatheter aortic valve implantation. ESC Heart Fail 2022; 9:1071-1079. [PMID: 35092186 PMCID: PMC8934930 DOI: 10.1002/ehf2.13774] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 10/31/2021] [Accepted: 12/02/2021] [Indexed: 12/19/2022] Open
Affiliation(s)
- Hatim Seoudy
- Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig‐Holstein, Campus Kiel Arnold‐Heller‐Str.3, Haus K3 Kiel 24105 Germany
- DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck Kiel Germany
| | - Mira Eberstein
- Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig‐Holstein, Campus Kiel Arnold‐Heller‐Str.3, Haus K3 Kiel 24105 Germany
| | - Johanne Frank
- Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig‐Holstein, Campus Kiel Arnold‐Heller‐Str.3, Haus K3 Kiel 24105 Germany
- DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck Kiel Germany
| | - Maren Thomann
- Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig‐Holstein, Campus Kiel Arnold‐Heller‐Str.3, Haus K3 Kiel 24105 Germany
| | - Thomas Puehler
- DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck Kiel Germany
- Department of Cardiac and Vascular Surgery University Hospital Schleswig‐Holstein, Campus Kiel Kiel Germany
| | - Georg Lutter
- DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck Kiel Germany
- Department of Cardiac and Vascular Surgery University Hospital Schleswig‐Holstein, Campus Kiel Kiel Germany
| | - Matthias Lutz
- Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig‐Holstein, Campus Kiel Arnold‐Heller‐Str.3, Haus K3 Kiel 24105 Germany
- DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck Kiel Germany
| | - Peter Bramlage
- Institute for Pharmacology and Preventive Medicine Cloppenburg Germany
| | - Norbert Frey
- Department of Cardiology, Angiology and Pneumology Heidelberg University Hospital Heidelberg Germany
- DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/Mannheim Heidelberg Germany
| | - Mohammed Saad
- Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig‐Holstein, Campus Kiel Arnold‐Heller‐Str.3, Haus K3 Kiel 24105 Germany
| | - Derk Frank
- Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig‐Holstein, Campus Kiel Arnold‐Heller‐Str.3, Haus K3 Kiel 24105 Germany
- DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck Kiel Germany
| |
Collapse
|
11
|
Herzig C, Frank J, Nenning A, Gerstl M, Bumberger A, Fleig J, Opitz AK, Limbeck A. Combining electrochemical and quantitative elemental analysis to investigate the sulfur poisoning process of ceria thin film fuel electrodes. J Mater Chem A Mater 2022; 10:1840-1851. [PMID: 35178245 PMCID: PMC8788136 DOI: 10.1039/d1ta06873c] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Accepted: 12/17/2021] [Indexed: 06/14/2023]
Abstract
This work deals with the effect of sulfur incorporation into model-type GDC thin films on their in-plane ionic conductivity. By means of impedance measurements, a strongly deteriorating effect on the grain boundary conductivity was confirmed, which additionally depends on the applied electrochemical polarisation. To quantify the total amount of sulfur incorporated into GDC thin films, online-laser ablation of solids in liquid (online-LASIL) was used as a novel solid sampling strategy. Online-LASIL combines several advantages of conventional sample introduction systems and enables the detection of S as a minor component in a very limited sample system (in the present case 35 μg total sample mass). To reach the requested sensitivity for S detection using an inductively coupled plasma-mass spectrometer (ICP-MS), the reaction cell of the quadrupole instrument was used and the parameters for the mass shift reaction with O2 were optimised. The combination of electrical and quantitative analytical results allows the identification of a potential sulfur incorporation pathway, which very likely proceeds along GDC grain boundaries with oxysulfide formation as the main driver of ion transport degradation. Depending on the applied cathodic bias, the measured amount of sulfur would be equivalent to 1-4 lattice constants of GDC transformed into an oxysulfide phase at the material's grain boundaries.
Collapse
Affiliation(s)
- C Herzig
- TU Wien, Institute of Chemical Technologies and Analytics Getreidemarkt 9/164 I2AC 1060 Vienna Austria
| | - J Frank
- TU Wien, Joint Workshop, Technical Chemistry Vienna Austria
| | - A Nenning
- TU Wien, Institute of Chemical Technologies and Analytics Getreidemarkt 9/164 I2AC 1060 Vienna Austria
| | - M Gerstl
- TU Wien, Institute of Chemical Technologies and Analytics Getreidemarkt 9/164 I2AC 1060 Vienna Austria
| | - A Bumberger
- TU Wien, Institute of Chemical Technologies and Analytics Getreidemarkt 9/164 I2AC 1060 Vienna Austria
| | - J Fleig
- TU Wien, Institute of Chemical Technologies and Analytics Getreidemarkt 9/164 I2AC 1060 Vienna Austria
| | - A K Opitz
- TU Wien, Institute of Chemical Technologies and Analytics Getreidemarkt 9/164 I2AC 1060 Vienna Austria
| | - A Limbeck
- TU Wien, Institute of Chemical Technologies and Analytics Getreidemarkt 9/164 I2AC 1060 Vienna Austria
| |
Collapse
|
12
|
Seoudy H, von Eberstein M, Frank J, Thomann M, Puehler T, Lutter G, Lutz M, Bramlage P, Frey N, Saad M, Frank D. TCT-411 Prognostic Implications of the HFA-PEFF Score in Patients With Preserved Ejection Fraction After Transcatheter Aortic Valve Replacement. J Am Coll Cardiol 2021. [DOI: 10.1016/j.jacc.2021.09.1264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
13
|
Voth M, Sommer K, Schindler C, Frank J, Marzi I. Rise of extremity fractures and sport accidents in children at 8-12 years and increase of admittance via the resuscitation room over a decade. Eur J Trauma Emerg Surg 2021; 48:3439-3448. [PMID: 34519864 PMCID: PMC9532303 DOI: 10.1007/s00068-021-01785-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2021] [Accepted: 09/01/2021] [Indexed: 11/26/2022]
Abstract
Introduction In an emergency department, the majority of pediatric trauma patients present because of minor injuries. The aim of this study was to evaluate temporal changes in age-related injury pattern, trauma mechanism, and surgeries in pediatric patients. Methods This retrospective study included patients < 18 years of age following trauma from 01/2009 to 12/2018 at a level I trauma center. They were divided into two groups: group A (A: 01/2009 to 12/2013) and group B (B: 01/2014 to 12/2018). Injury mechanism, injury pattern, and surgeries were analyzed. As major injuries fractures, dislocations, and organ injuries and as minor injuries contusions and superficial wounds were defined. Results 23,582 patients were included (58% male, median age 8.2 years). There was a slight increase in patients comparing A (n = 11,557) and B (n = 12,025) with no difference concerning demographic characteristics. Significant more patients (A: 1.9%; B: 2.4%) were admitted to resuscitation room, though the number of multiple injured patients was not significantly different. In A (25.5%), major injuries occurred significantly less frequently than in B (27.0%), minor injuries occurred equally. Extremity fractures were significantly more frequent in B (21.5%) than in A (20.2%), peaking at 8–12 years. Most trauma mechanisms of both groups were constant, with a rising of sport injuries at 8–12 years. Conclusion Although number of patients increases only slightly over a decade, there was a clear increase in major injuries, particularly extremity fractures, peaking at 8–12 years. At this age also sport accidents significantly increased. At least, admittance to resuscitation room rose but without an increase of multiple injured patients.
Collapse
Affiliation(s)
- M Voth
- Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
| | - K Sommer
- Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - C Schindler
- Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - J Frank
- Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - I Marzi
- Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| |
Collapse
|
14
|
Seoudy H, Saad M, Salem M, Allouch K, Frank J, Puehler T, Salem M, Lutter G, Kuhn C, Frank D. Calculated Plasma Volume Status Is Associated with Adverse Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation. J Clin Med 2021; 10:jcm10153333. [PMID: 34362114 PMCID: PMC8346970 DOI: 10.3390/jcm10153333] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Revised: 07/20/2021] [Accepted: 07/28/2021] [Indexed: 12/24/2022] Open
Abstract
Background: Calculated plasma volume status (PVS) reflects volume overload based on the deviation of the estimated plasma volume (ePV) from the ideal plasma volume (iPV). Calculated PVS is associated with prognosis in the context of heart failure. This single-center study investigated the prognostic impact of PVS in patients undergoing transcatheter aortic valve implantation (TAVI). Methods: A total of 859 TAVI patients had been prospectively enrolled in an observational study and were included in the analysis. An optimal cutoff for PVS of −5.4% was determined by receiver operating characteristic curve analysis. The primary endpoint was a composite of all-cause mortality or heart failure hospitalization within 1 year after TAVI. Results: A total of 324 patients had a PVS < −5.4% (no congestion), while 535 patients showed a PVS ≥ −5.4% (congestion). The primary endpoint occurred more frequently in patients with a PVS ≥ −5.4% compared to patients with PVS < −5.4% (22.6% vs. 13.0%, p < 0.001). After multivariable adjustment, PVS was confirmed as a significant predictor of the primary endpoint (HR 1.53, 95% CI 1.05–2.22, p = 0.026). Conclusions: Elevated PVS, as a marker of subclinical congestion, is significantly associated with all-cause mortality and heart failure hospitalization within 1 year after TAVI.
Collapse
Affiliation(s)
- Hatim Seoudy
- Department of Internal Medicine III, Cardiology and Angiology, Campus Kiel, University Hospital Schleswig-Holstein, D-24105 Kiel, Germany; (H.S.); (M.S.); (M.S.); (K.A.); (J.F.); (C.K.)
- DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, D-24105 Kiel, Germany; (T.P.); (M.S.); (G.L.)
| | - Mohammed Saad
- Department of Internal Medicine III, Cardiology and Angiology, Campus Kiel, University Hospital Schleswig-Holstein, D-24105 Kiel, Germany; (H.S.); (M.S.); (M.S.); (K.A.); (J.F.); (C.K.)
| | - Mostafa Salem
- Department of Internal Medicine III, Cardiology and Angiology, Campus Kiel, University Hospital Schleswig-Holstein, D-24105 Kiel, Germany; (H.S.); (M.S.); (M.S.); (K.A.); (J.F.); (C.K.)
| | - Kassem Allouch
- Department of Internal Medicine III, Cardiology and Angiology, Campus Kiel, University Hospital Schleswig-Holstein, D-24105 Kiel, Germany; (H.S.); (M.S.); (M.S.); (K.A.); (J.F.); (C.K.)
| | - Johanne Frank
- Department of Internal Medicine III, Cardiology and Angiology, Campus Kiel, University Hospital Schleswig-Holstein, D-24105 Kiel, Germany; (H.S.); (M.S.); (M.S.); (K.A.); (J.F.); (C.K.)
- DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, D-24105 Kiel, Germany; (T.P.); (M.S.); (G.L.)
| | - Thomas Puehler
- DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, D-24105 Kiel, Germany; (T.P.); (M.S.); (G.L.)
- Department of Cardiac and Vascular Surgery, Campus Kiel, University Hospital Schleswig-Holstein, D-24105 Kiel, Germany
| | - Mohamed Salem
- DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, D-24105 Kiel, Germany; (T.P.); (M.S.); (G.L.)
| | - Georg Lutter
- DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, D-24105 Kiel, Germany; (T.P.); (M.S.); (G.L.)
- Department of Cardiac and Vascular Surgery, Campus Kiel, University Hospital Schleswig-Holstein, D-24105 Kiel, Germany
| | - Christian Kuhn
- Department of Internal Medicine III, Cardiology and Angiology, Campus Kiel, University Hospital Schleswig-Holstein, D-24105 Kiel, Germany; (H.S.); (M.S.); (M.S.); (K.A.); (J.F.); (C.K.)
| | - Derk Frank
- Department of Internal Medicine III, Cardiology and Angiology, Campus Kiel, University Hospital Schleswig-Holstein, D-24105 Kiel, Germany; (H.S.); (M.S.); (M.S.); (K.A.); (J.F.); (C.K.)
- DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, D-24105 Kiel, Germany; (T.P.); (M.S.); (G.L.)
- Correspondence: ; Tel.: +49-(0)4-31500-22801
| |
Collapse
|
15
|
Berger S, Shaw DR, Berben T, Ouboter HT, In 't Zandt MH, Frank J, Reimann J, Jetten MSM, Welte CU. Current production by non-methanotrophic bacteria enriched from an anaerobic methane-oxidizing microbial community. Biofilm 2021; 3:100054. [PMID: 34308332 PMCID: PMC8258643 DOI: 10.1016/j.bioflm.2021.100054] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Revised: 04/12/2021] [Accepted: 05/19/2021] [Indexed: 12/21/2022] Open
Abstract
In recent years, the externalization of electrons as part of respiratory metabolic processes has been discovered in many different bacteria and some archaea. Microbial extracellular electron transfer (EET) plays an important role in many anoxic natural or engineered ecosystems. In this study, an anaerobic methane-converting microbial community was investigated with regard to its potential to perform EET. At this point, it is not well-known if or how EET confers a competitive advantage to certain species in methane-converting communities. EET was investigated in a two-chamber electrochemical system, sparged with methane and with an applied potential of +400 mV versus standard hydrogen electrode. A biofilm developed on the working electrode and stable low-density current was produced, confirming that EET indeed did occur. The appearance and presence of redox centers at −140 to −160 mV and at −230 mV in the biofilm was confirmed by cyclic voltammetry scans. Metagenomic analysis and fluorescence in situ hybridization of the biofilm showed that the anaerobic methanotroph ‘Candidatus Methanoperedens BLZ2’ was a significant member of the biofilm community, but its relative abundance did not increase compared to the inoculum. On the contrary, the relative abundance of other members of the microbial community significantly increased (up to 720-fold, 7.2% of mapped reads), placing these microorganisms among the dominant species in the bioanode community. This group included Zoogloea sp., Dechloromonas sp., two members of the Bacteroidetes phylum, and the spirochete Leptonema sp. Genes encoding proteins putatively involved in EET were identified in Zoogloea sp., Dechloromonas sp. and one member of the Bacteroidetes phylum. We suggest that instead of methane, alternative carbon sources such as acetate were the substrate for EET. Hence, EET in a methane-driven chemolithoautotrophic microbial community seems a complex process in which interactions within the microbial community are driving extracellular electron transfer to the electrode.
Collapse
Affiliation(s)
- S Berger
- Institute for Water and Wetland Research, Department of Microbiology, Radboud University, Nijmegen, the Netherlands
| | - D R Shaw
- Biological and Environmental Science and Engineering Division, Water Desalination and Reuse Research Center, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia.,Soehngen Institute of Anaerobic Microbiology, Radboud University, Nijmegen, the Netherlands
| | - T Berben
- Institute for Water and Wetland Research, Department of Microbiology, Radboud University, Nijmegen, the Netherlands
| | - H T Ouboter
- Institute for Water and Wetland Research, Department of Microbiology, Radboud University, Nijmegen, the Netherlands.,Soehngen Institute of Anaerobic Microbiology, Radboud University, Nijmegen, the Netherlands
| | - M H In 't Zandt
- Institute for Water and Wetland Research, Department of Microbiology, Radboud University, Nijmegen, the Netherlands.,Netherlands Earth System Science Center, Utrecht University, Utrecht, the Netherlands
| | - J Frank
- Institute for Water and Wetland Research, Department of Microbiology, Radboud University, Nijmegen, the Netherlands.,Soehngen Institute of Anaerobic Microbiology, Radboud University, Nijmegen, the Netherlands
| | - J Reimann
- Institute for Water and Wetland Research, Department of Microbiology, Radboud University, Nijmegen, the Netherlands
| | - M S M Jetten
- Institute for Water and Wetland Research, Department of Microbiology, Radboud University, Nijmegen, the Netherlands.,Netherlands Earth System Science Center, Utrecht University, Utrecht, the Netherlands.,Soehngen Institute of Anaerobic Microbiology, Radboud University, Nijmegen, the Netherlands
| | - C U Welte
- Institute for Water and Wetland Research, Department of Microbiology, Radboud University, Nijmegen, the Netherlands.,Soehngen Institute of Anaerobic Microbiology, Radboud University, Nijmegen, the Netherlands
| |
Collapse
|
16
|
Seoudy H, Al-Kassou B, Shamekhi J, Sugiura A, Frank J, Saad M, Bramlage P, Seoudy AK, Puehler T, Lutter G, Schulte DM, Laudes M, Nickenig G, Frey N, Sinning JM, Frank D. Frailty in patients undergoing transcatheter aortic valve replacement: prognostic value of the Geriatric Nutritional Risk Index. J Cachexia Sarcopenia Muscle 2021; 12:577-585. [PMID: 33764695 PMCID: PMC8200421 DOI: 10.1002/jcsm.12689] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Revised: 01/19/2021] [Accepted: 01/26/2021] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Malnutrition is a hallmark of frailty, is common among elderly patients, and is a predictor of poor outcomes in patients with severe symptomatic aortic stenosis (AS). The Geriatric Nutritional Risk Index (GNRI) is a simple and well-established screening tool to predict the risk of morbidity and mortality in elderly patients. In this study, we evaluated whether GNRI may be used in the risk stratification and management of patients undergoing transcatheter aortic valve replacement (TAVR). METHODS Patients with symptomatic severe AS (n = 953) who underwent transfemoral TAVR at the University Hospital Schleswig-Holstein Kiel, Germany, between 2010 and 2019 (development cohort) were divided into two groups: normal GNRI ≥ 98 (no nutrition-related risk; n = 618) versus low GNRI < 98 (at nutrition-related risk; n = 335). The results were validated in an independent (validation) cohort from another high-volume TAVR centre (n = 977). RESULTS The low-GNRI group had a higher proportion of female patients (59.1% vs. 52.1%), higher median age (82.9 vs. 81.8 years), prevalence of atrial fibrillation (50.4% vs. 40.0%), median logistic EuroSCORE (17.5% vs. 15.0%) and impaired left ventricular function (<35%: 10.7% vs. 6.8%), lower median estimated glomerular filtration rate (50 vs. 57 mL/min/1.73 m2 ) and median albumin level (3.5 vs. 4.0 g/dL) compared with the normal-GNRI group. Among peri-procedural complications, Acute Kidney Injury Network (AKIN) Stage 3 was more common in the low-GNRI group (3.6% vs. 0.6%, p = 0.002). After a mean follow-up of 21.1 months, all-cause mortality was significantly increased in the low-GNRI group compared with the normal-GNRI group (p < 0.001). This was confirmed in the validation cohort (p < 0.001). Low GNRI < 98 was identified as an independent risk factor for all-cause mortality (hazard ratio 1.44, 95% CI 1.01-2.04, p = 0.043). Other independent risk factors included albumin level < median of 4.0 g/dL, high-sensitive troponin T in the highest quartile (> 45.0 pg/mL), N-terminal pro-B-type natriuretic peptide in the highest quartile (> 3595 pg/mL), grade III-IV tricuspid regurgitation, pulmonary arterial hypertension, life-threatening bleeding, AKIN Stage 3 and disabling stroke. CONCLUSIONS Low GNRI score was associated with an increased risk of all-cause mortality in patients undergoing TAVR, implying that this vulnerable group may benefit from improved preventive measures.
Collapse
Affiliation(s)
- Hatim Seoudy
- Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, University Hospital Schleswig-Holstein Kiel, Kiel, Germany.,Partner Site Hamburg/Kiel/Lübeck, German Centre for Cardiovascular Research, Kiel, Germany
| | | | | | | | - Johanne Frank
- Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, University Hospital Schleswig-Holstein Kiel, Kiel, Germany.,Partner Site Hamburg/Kiel/Lübeck, German Centre for Cardiovascular Research, Kiel, Germany
| | - Mohammed Saad
- Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, University Hospital Schleswig-Holstein Kiel, Kiel, Germany
| | - Peter Bramlage
- Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany
| | - Anna Katharina Seoudy
- Department of Internal Medicine I, Division of Endocrinology, Diabetes and Clinical Nutrition, University of Kiel, Kiel, Germany
| | - Thomas Puehler
- Department of Cardiovascular Surgery, University Hospital Schleswig-Holstein Kiel, Kiel, Germany
| | - Georg Lutter
- Partner Site Hamburg/Kiel/Lübeck, German Centre for Cardiovascular Research, Kiel, Germany.,Department of Cardiovascular Surgery, University Hospital Schleswig-Holstein Kiel, Kiel, Germany
| | - Dominik M Schulte
- Department of Internal Medicine I, Division of Endocrinology, Diabetes and Clinical Nutrition, University of Kiel, Kiel, Germany
| | - Matthias Laudes
- Department of Internal Medicine I, Division of Endocrinology, Diabetes and Clinical Nutrition, University of Kiel, Kiel, Germany
| | - Georg Nickenig
- Heart Center Bonn, University Hospital Bonn, Bonn, Germany
| | - Norbert Frey
- Department of Cardiology, Heidelberg University, Heidelberg, Germany.,DZHK (German Center for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg University, Heidelberg, Germany
| | | | - Derk Frank
- Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, University Hospital Schleswig-Holstein Kiel, Kiel, Germany.,Partner Site Hamburg/Kiel/Lübeck, German Centre for Cardiovascular Research, Kiel, Germany
| |
Collapse
|
17
|
Seoudy H, Lambers M, Winkler V, Dudlik L, Freitag-Wolf S, Frank J, Kuhn C, Rangrez AY, Puehler T, Lutter G, Bramlage P, Frey N, Frank D. Elevated high-sensitivity troponin T levels at 1-year follow-up are associated with increased long-term mortality after TAVR. Clin Res Cardiol 2020; 110:421-428. [PMID: 33098469 PMCID: PMC7907029 DOI: 10.1007/s00392-020-01759-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Accepted: 10/05/2020] [Indexed: 11/04/2022]
Abstract
Background Elevated pre-procedural high-sensitivity troponin T (hs-TnT) levels predict adverse outcomes in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). It is unknown whether elevated troponin levels still provide prognostic information during follow-up after successful TAVR. We evaluated the long-term implications of elevated hs-TnT levels found at 1-year post-TAVR. Methods and results The study included 349 patients who underwent TAVR for severe AS from 2010–2019 and for whom 1-year hs-TnT levels were available. Any required percutaneous coronary interventions were performed > 1 week before TAVR. The primary endpoint was survival time starting at 1-year post-TAVR. Optimal hs-TnT cutoff for stratifying risk, identified by ROC analysis, was 39.4 pg/mL. 292 patients had hs-TnT < 39.4 pg/mL (median 18.3 pg/mL) and 57 had hs-TnT ≥ 39.4 pg/mL (median 51.2 pg/mL). The high hs-TnT group had a higher median N-terminal pro-B-type natriuretic peptide (NT-proBNP) level, greater left ventricular (LV) mass, higher prevalence of severe diastolic dysfunction, LV ejection fraction < 35%, severe renal dysfunction, and more men compared with the low hs-TnT group. All-cause mortality during follow-up after TAVR was significantly higher among patients who had hs-TnT ≥ 39.4 pg/mL compared with those who did not (mortality rate at 2 years post-TAVR: 12.3% vs. 4.1%, p = 0.010). Multivariate analysis identified 1-year hs-TnT ≥ 39.4 pg/mL (hazard ratio 2.93, 95% CI 1.91–4.49, p < 0.001), NT-proBNP level > 300 pg/mL, male sex, an eGFR < 60 mL/min/1.73 m2 and chronic obstructive pulmonary disease as independent risk factors for long-term mortality after TAVR. Conclusions Elevated hs-TnT concentrations at 1-year after TAVR were associated with a higher long-term mortality. Graphic abstract ![]()
Collapse
Affiliation(s)
- Hatim Seoudy
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein Kiel, Arnold-Heller-Str.3, Haus K3, 24105, Kiel, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/ Kiel/ Lübeck, Kiel, Germany
| | - Moritz Lambers
- Department of Cardiology and Angiology, Contilia Heart and Vascular Centre Elisabeth-Krankenhaus, Essen, Germany
| | - Vincent Winkler
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein Kiel, Arnold-Heller-Str.3, Haus K3, 24105, Kiel, Germany
| | - Linnea Dudlik
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein Kiel, Arnold-Heller-Str.3, Haus K3, 24105, Kiel, Germany
| | - Sandra Freitag-Wolf
- Department of Medical Informatics and Statistics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Johanne Frank
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein Kiel, Arnold-Heller-Str.3, Haus K3, 24105, Kiel, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/ Kiel/ Lübeck, Kiel, Germany
| | - Christian Kuhn
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein Kiel, Arnold-Heller-Str.3, Haus K3, 24105, Kiel, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/ Kiel/ Lübeck, Kiel, Germany
| | - Ashraf Yusuf Rangrez
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein Kiel, Arnold-Heller-Str.3, Haus K3, 24105, Kiel, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/ Kiel/ Lübeck, Kiel, Germany
| | - Thomas Puehler
- DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/ Kiel/ Lübeck, Kiel, Germany.,Department of Cardiovascular Surgery, University Hospital Schleswig-Holstein, Kiel, Germany
| | - Georg Lutter
- DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/ Kiel/ Lübeck, Kiel, Germany.,Department of Cardiovascular Surgery, University Hospital Schleswig-Holstein, Kiel, Germany
| | - Peter Bramlage
- Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany
| | - Norbert Frey
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein Kiel, Arnold-Heller-Str.3, Haus K3, 24105, Kiel, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/ Kiel/ Lübeck, Kiel, Germany
| | - Derk Frank
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein Kiel, Arnold-Heller-Str.3, Haus K3, 24105, Kiel, Germany. .,DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/ Kiel/ Lübeck, Kiel, Germany.
| |
Collapse
|
18
|
Seoudy H, Shamekhi J, Frank J, Herfett I, Al-Kassou B, Sugiura A, Puehler T, Lutter G, Treede H, Nickenig G, Frey N, Sinning JM, Frank D. TCT CONNECT-147 Limitations of Established Cardiac Biomarkers in Low-to Intermediate-Risk TF-TAVR Patients With Advanced CKD. J Am Coll Cardiol 2020. [DOI: 10.1016/j.jacc.2020.09.558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
19
|
Hermasch MA, Schön MP, Frank J. Comorbid acne inversa and Dowling-Degos disease due to a single NCSTN mutation: is there enough evidence? Br J Dermatol 2020; 184:374. [PMID: 32894577 DOI: 10.1111/bjd.19539] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Accepted: 08/31/2020] [Indexed: 12/19/2022]
Affiliation(s)
- M A Hermasch
- Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Robert Koch Straße 40, 37075, Göttingen, Germany
| | - M P Schön
- Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Robert Koch Straße 40, 37075, Göttingen, Germany.,Lower Saxony Institute of Occupational Dermatology, University Medical Center Göttingen, Göttingen, Germany
| | - J Frank
- Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Robert Koch Straße 40, 37075, Göttingen, Germany
| |
Collapse
|
20
|
Lang M, Leménager T, Streit F, Fauth-Bühler M, Frank J, Juraeva D, Witt S, Degenhardt F, Hofmann A, Heilmann-Heimbach S, Kiefer F, Brors B, Grabe HJ, John U, Bischof A, Bischof G, Völker U, Homuth G, Beutel M, Lind P, Medland S, Slutske W, Martin N, Völzke H, Nöthen M, Meyer C, Rumpf HJ, Wurst F, Rietschel M, Mann K. Genome-wide association study of pathological gambling. Eur Psychiatry 2020; 36:38-46. [DOI: 10.1016/j.eurpsy.2016.04.001] [Citation(s) in RCA: 74] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2015] [Revised: 03/09/2016] [Accepted: 04/01/2016] [Indexed: 12/18/2022] Open
Abstract
AbstractBackgroundPathological gambling is a behavioural addiction with negative economic, social, and psychological consequences. Identification of contributing genes and pathways may improve understanding of aetiology and facilitate therapy and prevention. Here, we report the first genome-wide association study of pathological gambling. Our aims were to identify pathways involved in pathological gambling, and examine whether there is a genetic overlap between pathological gambling and alcohol dependence.MethodsFour hundred and forty-five individuals with a diagnosis of pathological gambling according to the Diagnostic and Statistical Manual of Mental Disorders were recruited in Germany, and 986 controls were drawn from a German general population sample. A genome-wide association study of pathological gambling comprising single marker, gene-based, and pathway analyses, was performed. Polygenic risk scores were generated using data from a German genome-wide association study of alcohol dependence.ResultsNo genome-wide significant association with pathological gambling was found for single markers or genes. Pathways for Huntington's disease (P-value = 6.63 × 10−3); 5′-adenosine monophosphate-activated protein kinase signalling (P-value = 9.57 × 10−3); and apoptosis (P-value = 1.75 × 10−2) were significant. Polygenic risk score analysis of the alcohol dependence dataset yielded a one-sided nominal significant P-value in subjects with pathological gambling, irrespective of comorbid alcohol dependence status.ConclusionsThe present results accord with previous quantitative formal genetic studies which showed genetic overlap between non-substance- and substance-related addictions. Furthermore, pathway analysis suggests shared pathology between Huntington's disease and pathological gambling. This finding is consistent with previous imaging studies.
Collapse
|
21
|
Seoudy H, Frank J, Neu M, Güßefeld N, Klaus Y, Freitag-Wolf S, Lambers M, Lutter G, Dempfle A, Rangrez AY, Kuhn C, Frey N, Frank D. Periprocedural Changes of NT-proBNP Are Associated With Survival After Transcatheter Aortic Valve Implantation. J Am Heart Assoc 2020; 8:e010876. [PMID: 30686097 PMCID: PMC6405592 DOI: 10.1161/jaha.118.010876] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Background Cardiovascular biomarkers constitute promising tools for improved risk stratification and prediction of outcome in patients undergoing transcatheter aortic valve implantation. We examined the association of periprocedural changes of NT‐proBNP (N‐terminal pro–B‐type natriuretic peptide) with survival after transcatheter aortic valve implantation. Methods and Results NT‐proBNP levels were measured in 704 patients before transcatheter aortic valve implantation and at discharge. Patients were grouped as responders and nonresponders depending on an NT‐proBNP–based ratio (postprocedural NT‐proBNP at discharge/preprocedural NT‐proBNP). Overall, 376 of 704 patients showed a postprocedural decrease in NT‐proBNP levels (NT‐proBNP ratio <1). Responders and nonresponders differed significantly regarding median preprocedural (2822 versus 1187 pg/mL, P<0.001) and postprocedural (1258 versus 3009 pg/mL, P<0.001) NT‐proBNP levels. Patients in the nonresponder group showed higher prevalence of atrial fibrillation (47.0% versus 39.4%, P=0.042), arterial hypertension (94.2% versus 87.5%, P=0.002), renal impairment (77.4% versus 69.1%, P=0.013), and peripheral artery disease (24.4% versus 14.6%, P=0.001). In contrast, patients in the responder group had higher prevalence of moderately reduced left ventricular ejection fraction (17.3% versus 11.0%, P=0.017), lower calculated aortic valve area (0.7 versus 0.8 cm2, P<0.001), and higher mean pressure gradient (41 versus 35 mm Hg, P<0.001). Median follow‐up was 22.6 months. Kaplan–Meier analysis showed a highly significant survival benefit for the responder group compared with the nonresponder group (log‐rank test, P<0.001). Conclusions A ratio based on periprocedural changes of NT‐proBNP is a simple tool for better risk stratification and is associated with survival in patients after transcatheter aortic valve implantation.
Collapse
Affiliation(s)
- Hatim Seoudy
- 1 Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig-Holstein Kiel Germany
| | - Johanne Frank
- 1 Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig-Holstein Kiel Germany
| | - Markus Neu
- 1 Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig-Holstein Kiel Germany
| | - Nathalie Güßefeld
- 1 Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig-Holstein Kiel Germany
| | - Yannic Klaus
- 1 Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig-Holstein Kiel Germany
| | - Sandra Freitag-Wolf
- 2 Institute of Medical Informatics and Statistics Kiel University University Hospital Schleswig-Holstein Kiel Germany
| | - Moritz Lambers
- 1 Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig-Holstein Kiel Germany.,3 Department of Cardiology and Angiology Contilia Heart and Vascular Centre Elisabeth-Krankenhaus Essen Germany
| | - Georg Lutter
- 4 Department of Cardiovascular Surgery University Hospital Schleswig-Holstein Kiel Germany.,5 DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck Kiel Germany
| | - Astrid Dempfle
- 2 Institute of Medical Informatics and Statistics Kiel University University Hospital Schleswig-Holstein Kiel Germany
| | - Ashraf Yusuf Rangrez
- 1 Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig-Holstein Kiel Germany.,5 DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck Kiel Germany
| | - Christian Kuhn
- 1 Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig-Holstein Kiel Germany.,5 DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck Kiel Germany
| | - Norbert Frey
- 1 Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig-Holstein Kiel Germany.,5 DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck Kiel Germany
| | - Derk Frank
- 1 Department of Internal Medicine III, Cardiology and Angiology University Hospital Schleswig-Holstein Kiel Germany.,5 DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck Kiel Germany
| |
Collapse
|
22
|
Seoudy H, Kuhn C, Frank J, Eden M, Rangrez AY, Lutter G, Frey N, Frank D. Prognostic implications of N-terminal pro-B-type natriuretic peptide in patients with normal left ventricular ejection fraction undergoing transcatheter aortic valve implantation. Int J Cardiol 2019; 301:195-199. [PMID: 31757644 DOI: 10.1016/j.ijcard.2019.11.101] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Revised: 09/16/2019] [Accepted: 11/11/2019] [Indexed: 01/29/2023]
Abstract
BACKGROUND Biomarkers may significantly improve risk stratification algorithms for patients undergoing transcatheter aortic valve implantation (TAVI). While N-terminal pro-B-type natriuretic peptide (NT-proBNP) is established as a biomarker in the context of heart failure, its prognostic implications in patients with normal left ventricular ejection fraction (LVEF) undergoing TAVI are unclear. METHODS A total of 504 TAVI patients with normal LVEF were analyzed. Based on preprocedural NT-proBNP levels, patients were stratified into two groups comparing the upper quartile ("Q4", n = 126) with the lower three quartiles ("Q1-3", n = 378). The primary outcome of our study was survival. RESULTS The "Q4" group included more men (46.8% vs. 34.9%, p = 0.017), had higher rates of atrial fibrillation (55.6% vs. 28.3%, p < 0.001) and showed features of more advanced aortic stenosis (mean pressure gradient 49 mmHg vs. 40 mmHg, aortic valve area 0.6 cm2 vs. 0.7 cm2; p < 0.001, respectively). The "Q4" group was also characterized by more extensive cardiac remodeling including severe diastolic dysfunction (18.1% vs. 6.5%, p < 0.001) and left atrial dilation (26.8% vs. 10.8%, p < 0.001). Kaplan-Meier analysis demonstrated superior survival of the "Q1-3" group (median follow-up 22.1 months, log-rank test p < 0.001). In a multivariable analysis, preprocedural NT-proBNP emerged as a significant risk factor for all-cause mortality after TAVI (HR 1.87, CI 1.31-2.65, p < 0.001). CONCLUSIONS NT-proBNP is associated with survival in TAVI patients with normal LVEF. In this patient group, preprocedural NT-proBNP levels do not only correlate with aortic stenosis, but reflect advanced cardiovascular dysfunction, including HFpEF, that might not be completely reversible after TAVI.
Collapse
Affiliation(s)
- Hatim Seoudy
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Kiel, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Hamburg/Kiel/Lübeck, Kiel, Germany
| | - Christian Kuhn
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Kiel, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Hamburg/Kiel/Lübeck, Kiel, Germany
| | - Johanne Frank
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Kiel, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Hamburg/Kiel/Lübeck, Kiel, Germany
| | - Matthias Eden
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Kiel, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Hamburg/Kiel/Lübeck, Kiel, Germany
| | - Ashraf Yusuf Rangrez
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Kiel, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Hamburg/Kiel/Lübeck, Kiel, Germany
| | - Georg Lutter
- DZHK (German Centre for Cardiovascular Research), Partner site Hamburg/Kiel/Lübeck, Kiel, Germany; Department of Cardiovascular Surgery, University Hospital Schleswig-Holstein, Kiel, Germany
| | - Norbert Frey
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Kiel, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Hamburg/Kiel/Lübeck, Kiel, Germany
| | - Derk Frank
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Kiel, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Hamburg/Kiel/Lübeck, Kiel, Germany.
| |
Collapse
|
23
|
Maffia M, Vergara D, Romano A, Corricciati C, Damato M, Frank J, Fournier I, Salzet M, Quattrini A. Spatio-temporal analysis of rat peripheral nerve regeneration. J Biotechnol 2019. [DOI: 10.1016/j.jbiotec.2019.05.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Dathe K, Frank J, Padberg S, Hultzsch S, Meixner K, Beck E, Meister R, Schaefer C. Negligible risk of prenatal ductus arteriosus closure or fetal renal impairment after third‐trimester paracetamol use: evaluation of the German Embryotox cohort. BJOG 2019; 126:1560-1567. [DOI: 10.1111/1471-0528.15872] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/05/2019] [Indexed: 11/28/2022]
Affiliation(s)
- K Dathe
- Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin Humboldt‐Universität zu Berlin, and Berlin Institute of Health Institut für Klinische Pharmakologie und Toxikologie Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie Berlin Germany
| | - J Frank
- Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin Humboldt‐Universität zu Berlin, and Berlin Institute of Health Institut für Klinische Pharmakologie und Toxikologie Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie Berlin Germany
| | - S Padberg
- Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin Humboldt‐Universität zu Berlin, and Berlin Institute of Health Institut für Klinische Pharmakologie und Toxikologie Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie Berlin Germany
| | - S Hultzsch
- Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin Humboldt‐Universität zu Berlin, and Berlin Institute of Health Institut für Klinische Pharmakologie und Toxikologie Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie Berlin Germany
| | - K Meixner
- Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin Humboldt‐Universität zu Berlin, and Berlin Institute of Health Institut für Klinische Pharmakologie und Toxikologie Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie Berlin Germany
| | - E Beck
- Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin Humboldt‐Universität zu Berlin, and Berlin Institute of Health Institut für Klinische Pharmakologie und Toxikologie Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie Berlin Germany
| | - R Meister
- Department of Mathematics Beuth Hochschule für Technik—University of Applied Sciences Berlin Germany
| | - C Schaefer
- Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin Humboldt‐Universität zu Berlin, and Berlin Institute of Health Institut für Klinische Pharmakologie und Toxikologie Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie Berlin Germany
| |
Collapse
|
25
|
Frank J, Betz RC. Haaranomalien bei syndromalen Erkrankungen. Hautarzt 2019; 70:514-519. [DOI: 10.1007/s00105-019-4440-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
26
|
Abstract
Skin tumors can manifest solitarily and sporadically but can also be multiple and familial. Beside the skin, hereditary cutaneous tumor syndromes also affect extracutaneous organs and are clinically and genetically heterogeneous. Taking the medical history, a clinical examination and dermatopathological characterization of the respective neoplasia will help the dermatologist to reach a diagnosis at an early stage. Subsequently, this diagnosis can be unambiguously confirmed by molecular genetic analysis. Here, we provide an overview and update on selected hereditary cutaneous tumor syndromes.
Collapse
Affiliation(s)
- M A Hermasch
- Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland
| | - J Frank
- Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland.
| |
Collapse
|
27
|
Frank D, Seoudy H, Kujat T, Frank J, Lutter G, Rangrez AY, Kuhn C, Frey N. PROGNOSTIC VALUE OF THE C-REACTIVE PROTEIN/ALBUMIN RATIO IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION. J Am Coll Cardiol 2019. [DOI: 10.1016/s0735-1097(19)32608-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
28
|
Schweiger JI, Bilek E, Schäfer A, Braun U, Moessnang C, Harneit A, Post P, Otto K, Romanczuk-Seiferth N, Erk S, Wackerhagen C, Mattheisen M, Mühleisen TW, Cichon S, Nöthen MM, Frank J, Witt SH, Rietschel M, Heinz A, Walter H, Meyer-Lindenberg A, Tost H. Effects of BDNF Val 66Met genotype and schizophrenia familial risk on a neural functional network for cognitive control in humans. Neuropsychopharmacology 2019; 44:590-597. [PMID: 30375508 PMCID: PMC6333795 DOI: 10.1038/s41386-018-0248-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2018] [Revised: 09/25/2018] [Accepted: 10/16/2018] [Indexed: 12/16/2022]
Abstract
Cognitive control represents an essential neuropsychological characteristic that allows for the rapid adaption of a changing environment by constant re-allocation of cognitive resources. This finely tuned mechanism is impaired in psychiatric disorders such as schizophrenia and contributes to cognitive deficits. Neuroimaging has highlighted the contribution of the anterior cingulate cortex (ACC) and prefrontal regions (PFC) on cognitive control and demonstrated the impact of genetic variation, as well as genetic liability for schizophrenia. In this study, we aimed to examine the influence of the functional single-nucleotide polymorphism (SNP) rs6265 of a plasticity-related neurotrophic factor gene, BDNF (Val66Met), on cognitive control. Strong evidence implicates BDNF Val66Met in neural plasticity in humans. Furthermore, several studies suggest that although the variant is not convincingly associated with schizophrenia risk, it seems to be a modifier of the clinical presentation and course of the disease. In order to clarify the underlying mechanisms using functional magnetic resonance imaging (fMRI), we studied the effects of this SNP on ACC and PFC activation, and the connectivity between these regions in a discovery sample of 85 healthy individuals and sought to replicate this effect in an independent sample of 253 individuals. Additionally, we tested the identified imaging phenotype in relation to schizophrenia familial risk in a sample of 58 unaffected first-degree relatives of schizophrenia patients. We found a significant increase in interregional connectivity between ACC and PFC in the risk-associated BDNF 66Met allele carriers. Furthermore, we replicated this effect in an independent sample and demonstrated its independence of structural confounds, as well as task specificity. A similar coupling increase was detectable in individuals with increased familial risk for schizophrenia. Our results show that a key neural circuit for cognitive control is influenced by a plasticity-related genetic variant, which may render this circuit particular susceptible to genetic and environmental risk factors for schizophrenia.
Collapse
Affiliation(s)
- J. I. Schweiger
- 0000 0001 2190 4373grid.7700.0Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - E. Bilek
- 0000 0001 2190 4373grid.7700.0Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - A. Schäfer
- 0000 0001 2190 4373grid.7700.0Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - U. Braun
- 0000 0001 2190 4373grid.7700.0Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - C. Moessnang
- 0000 0001 2190 4373grid.7700.0Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - A. Harneit
- 0000 0001 2190 4373grid.7700.0Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - P. Post
- 0000 0001 2190 4373grid.7700.0Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - K. Otto
- 0000 0001 2190 4373grid.7700.0Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - N. Romanczuk-Seiferth
- 0000 0001 2218 4662grid.6363.0Department of Psychiatry and Psychotherapy, Charité - University Medicine Berlin, Campus Mitte, Berlin, Germany
| | - S. Erk
- 0000 0001 2218 4662grid.6363.0Department of Psychiatry and Psychotherapy, Charité - University Medicine Berlin, Campus Mitte, Berlin, Germany
| | - C. Wackerhagen
- 0000 0001 2218 4662grid.6363.0Department of Psychiatry and Psychotherapy, Charité - University Medicine Berlin, Campus Mitte, Berlin, Germany
| | - M. Mattheisen
- 0000 0001 1956 2722grid.7048.bDepartment of Biomedicine and Centre for Integrative Sequencing, iSEQ Aarhus University, Aarhus, Denmark ,grid.452548.a0000 0000 9817 5300The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus and Copenhagen, Denmark
| | - T. W. Mühleisen
- 0000 0001 2297 375Xgrid.8385.6Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, Jülich, Germany ,0000 0004 1937 0642grid.6612.3Department of Biomedicine, University of Basel, Basel, Switzerland
| | - S. Cichon
- 0000 0001 2297 375Xgrid.8385.6Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, Jülich, Germany ,grid.410567.1Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland
| | - M. M. Nöthen
- 0000 0001 2240 3300grid.10388.32Institute of Human Genetics, University of Bonn, Sigmund-Freud-Str. 25, Bonn, 53127 Germany ,0000 0001 2240 3300grid.10388.32Department of Genomics, Life & Brain Center, University of Bonn, Sigmund-Freud-Str. 25, Bonn, 53127 Germany
| | - J. Frank
- 0000 0001 2190 4373grid.7700.0Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - S. H. Witt
- 0000 0001 2190 4373grid.7700.0Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - M. Rietschel
- 0000 0001 2190 4373grid.7700.0Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - A. Heinz
- 0000 0001 2218 4662grid.6363.0Department of Psychiatry and Psychotherapy, Charité - University Medicine Berlin, Campus Mitte, Berlin, Germany
| | - H. Walter
- 0000 0001 2218 4662grid.6363.0Department of Psychiatry and Psychotherapy, Charité - University Medicine Berlin, Campus Mitte, Berlin, Germany
| | - A. Meyer-Lindenberg
- 0000 0001 2190 4373grid.7700.0Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - H. Tost
- 0000 0001 2190 4373grid.7700.0Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| |
Collapse
|
29
|
Frank J, Kietzman K, Damron-Rodriguez J, Palimaru A, del Pino H, Regos-Stewart D. CALIFORNIA’S MENTAL HEALTH SERVICES ACT: DOES IT SUPPORT AN OLDER ADULT SYSTEM OF CARE? Innov Aging 2018. [DOI: 10.1093/geroni/igy023.1998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- J Frank
- UCLA Center for Health Policy Research
| | | | | | | | - H del Pino
- Charles R. Drew University of Medicine and Science
| | | |
Collapse
|
30
|
Parren L, Baron J, Joussen S, Marquardt Y, Hanneken S, van Steensel M, Steijlen P, van Geel M, Frank J. CYLD
mutations differentially affect splicing and mRNA decay in Brooke-Spiegler syndrome. J Eur Acad Dermatol Venereol 2018; 32:e331-e333. [DOI: 10.1111/jdv.14889] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- L.J.M.T. Parren
- Department of Dermatology; Jeroen Bosch Hospital; ‘s-Hertogenbosch The Netherlands
- Department of Dermatology; Maastricht University Medical Center (MUMC); Maastricht The Netherlands
- GROW - School for Oncology and Developmental Biology; Maastricht University Medical Center (MUMC); Maastricht The Netherlands
| | - J.M. Baron
- Department of Dermatology and Allergology; RWTH Aachen University; Aachen Germany
| | - S. Joussen
- Institute of Physiology; RWTH Aachen University; Aachen Germany
| | - Y. Marquardt
- Department of Dermatology and Allergology; RWTH Aachen University; Aachen Germany
| | - S. Hanneken
- Private Practice Empoderm; Düsseldorf Germany
| | - M.A.M. van Steensel
- Institute of Medical Biology; Immunos; Singapore Singapore
- Division of Cancer Science; College of Medicine, Dentistry and Nursing; University of Dundee; Dundee UK
- Department of Biological Chemistry and Drug Discover; College of Life Sciences; University of Dundee; Dundee UK
| | - P.M. Steijlen
- Department of Dermatology; Maastricht University Medical Center (MUMC); Maastricht The Netherlands
- GROW - School for Oncology and Developmental Biology; Maastricht University Medical Center (MUMC); Maastricht The Netherlands
| | - M. van Geel
- Department of Dermatology; Maastricht University Medical Center (MUMC); Maastricht The Netherlands
- GROW - School for Oncology and Developmental Biology; Maastricht University Medical Center (MUMC); Maastricht The Netherlands
- Department of Clinical Genetics; Maastricht University Medical Center; Maastricht The Netherlands
| | - J. Frank
- Department of Dermatology, Venereology and Allergology; University Medical Center Göttingen; Göttingen Germany
| |
Collapse
|
31
|
Haux R, Frank J, Knaup P. The IMIA WGI Database on Health and Medical Informatics Programs and Courses: A Call for Participation. Methods Inf Med 2018. [DOI: 10.1055/s-0038-1636844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Working Group 1 on health and medical informatics education of the International Medical Informatics Association (IMIA) has established a WWW site (http://ix.urz.uni-heidelberg.de/ ~ d16) to provide up-to-date information about its work. The core of the site is an underlying database providing information on health and medical informatics (HMI) programs and courses worldwide. To be able to have a database of high quality and value we encourage all teachers and institutions to submit information about courses and programs on HMI education offered and to set pointers to their own WWW sites. In addition, a mailing list was installed to facilitate communication between all persons interested in HMI education. For subscription a message has to be sent to “listserv@listserv.net”. The body of the message should read “SUBSCRIBE IMIA-WG1”. Messages to the IMIAWG1 list have to be sent to “imia-wg1@urzinfo.urz.uni-heidelberg.de”.
Collapse
|
32
|
Humbatova A, Maroofian R, Romano MT, Tafazzoli A, Behnam M, Dilaver N, Nouri N, Salehi M, Wolf S, Frank J, Kokordelis P, Betz RC. An insertion mutation in HOXC13 underlies pure hair and nail ectodermal dysplasia with lacrimal duct obstruction. Br J Dermatol 2017; 178:e265-e267. [PMID: 29278420 DOI: 10.1111/bjd.16276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- A Humbatova
- Institute of Human Genetics, University Hospital Bonn, Bonn, Germany.,Institute of Genetic Resources, Azerbaijan, National Academy of Sciences, Baku, Azerbaijan
| | - R Maroofian
- Molecular & Clinical Sciences Research Institute, St. George's University of London, Cranmer Terrace, London, U.K
| | - M-T Romano
- Institute of Human Genetics, University Hospital Bonn, Bonn, Germany
| | - A Tafazzoli
- Institute of Human Genetics, University Hospital Bonn, Bonn, Germany
| | - M Behnam
- Medical Genetics Laboratory of Genome, Isfahan, Iran
| | - N Dilaver
- Swansea University Medical School, Swansea University, Wales, U.K
| | - N Nouri
- Medical Genetics Laboratory of Genome, Isfahan, Iran
| | - M Salehi
- Medical Genetics Laboratory of Genome, Isfahan, Iran.,Division of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - S Wolf
- Institute of Human Genetics, University Hospital Bonn, Bonn, Germany
| | - J Frank
- Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany
| | - P Kokordelis
- Institute of Human Genetics, University Hospital Bonn, Bonn, Germany
| | - R C Betz
- Institute of Human Genetics, University Hospital Bonn, Bonn, Germany
| |
Collapse
|
33
|
Ralser DJ, Lestringant GG, Du-Thanh A, Kokordelis P, Fischer J, Basmanav FBÜ, Wolf S, Thiele H, Altmüller J, Nürnberg P, Oji V, Fritz G, Frank J, Betz RC. Functional implications of novel ADAM10 mutations in reticulate acropigmentation of Kitamura. Br J Dermatol 2017; 177:e340-e343. [PMID: 29192958 DOI: 10.1111/bjd.16024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- D J Ralser
- Institute of Human Genetics, University of Bonn, Bonn, Germany
| | - G G Lestringant
- Consultant dermatologist (retired), British Ministry of Defence, London, U.K
| | - A Du-Thanh
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - P Kokordelis
- Institute of Human Genetics, University of Bonn, Bonn, Germany
| | - J Fischer
- Institute of Human Genetics, University of Bonn, Bonn, Germany
| | | | - S Wolf
- Institute of Human Genetics, University of Bonn, Bonn, Germany
| | - H Thiele
- Cologne Center for Genomics, University of Cologne, Cologne, Germany
| | - J Altmüller
- Cologne Center for Genomics, University of Cologne, Cologne, Germany.,Institute of Human Genetics, University of Cologne, Cologne, Germany
| | - P Nürnberg
- Cologne Center for Genomics, University of Cologne, Cologne, Germany.,Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany.,Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany
| | - V Oji
- Department of Dermatology, University of Münster, Münster, Germany
| | - G Fritz
- Institute of Neuropathology, Neurozentrum, University of Freiburg, Freiburg, Germany
| | - J Frank
- Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany
| | - R C Betz
- Institute of Human Genetics, University of Bonn, Bonn, Germany
| |
Collapse
|
34
|
Pearce J, Best C, Haseen F, Currie D, MacKintosh1 AM, Stead M, Eadie D, MacGregor A, Amos A, Frank J, Haw S. Electronic cigarette use and smoking initiation in Scottish adolescents: a cohort study. Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx187.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- J Pearce
- University of Edinburgh, Edinburgh, UK
| | - C Best
- University of Stirling, Stirling, UK
| | - F Haseen
- University of St Andrews, St Andrews, UK
| | - D Currie
- University of St Andrews, St Andrews, UK
| | | | - M Stead
- University of Stirling, Stirling, UK
| | - D Eadie
- University of Stirling, Stirling, UK
| | | | - A Amos
- University of Edinburgh, Edinburgh, UK
| | - J Frank
- University of Edinburgh, Edinburgh, UK
| | - S Haw
- University of Stirling, Stirling, UK
| |
Collapse
|
35
|
Abstract
INTRODUCTION Beside serious and potentially fatal injuries, the majority of pediatric trauma patients present with minor injuries to emergency departments. The aim of this study was to evaluate age-related injury pattern, trauma mechanism as well as the need for surgery in pediatric patients. PATIENTS AND METHODS Retrospective Study from 01/2008 to 12/2012 at a level I trauma center. All patients <18years of age following trauma were included. Injury mechanism, injury pattern as well as need for surgery were analyzed according to different age groups (0-3 years, 4-7 years, 8-12 years and 13-17 years). Major injuries were defined as fractures, dislocations and visceral organ injuries. Minor injuries included contusions and superficial wounds. RESULTS Overall, 15300 patients were included (59% male, median age 8 years). A total of 303 patients (2%) were admitted to the resuscitation room and of these, 69 (0.5% of all patients) were multiply injured (median Injury Severity Score (ISS) 20 pts). Major injuries were found in 3953 patients (26%). Minor injuries were documented in 11347 patients (74%). Of those patients with a major injury, 76% (2991 patients) suffered a fracture, 3% (132 patients) a dislocation and 3% (131 patients) an injury of nerves, tendons or ligaments. The majority of fractures were located in the upper extremity (73%) (elbow fractures 16%; radius fractures 16%; finger fractures 14%). Patients with minor injuries presented with head injuries (34%), finger injuries (10%) and injuries of the upper ankle (9%). The most common trauma mechanisms included impact (41%), followed by falls from standing height (24%), sport injuries (15%) and traffic accidents (9%). Overall, 1558 patients (10%) were operated. Of these, 61% had a major and 39% a minor injury. CONCLUSION Almost 75% of all children, who presented to the emergency department following trauma revealed minor injuries. However, 25% suffered a relevant, major injury and 0.5% suffered a multiple trauma with a median ISS of 20. Overall, 10% had to be operated. The most frequently found major injuries were extremity fractures, with elbow fractures as the most common fracture.
Collapse
Affiliation(s)
- M Voth
- Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
| | - T Lustenberger
- Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
| | - B Auner
- Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
| | - J Frank
- Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
| | - I Marzi
- Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
| |
Collapse
|
36
|
Frank J, Lee Y, Kim D, Benaim E. RX-3117, a novel hypomethylating agent, shows promising therapeutic activity in combination with nab-paclitaxel and check-point inhibitors in preclinical models. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
37
|
Zheng N, Sherif N, Li Q, Broyles I, Chong N, Frank J, Rokoske F. COMPREHENSIVE ASSESSMENT UPON HOSPICE ADMISSION: WHAT DRIVES NON-COMPLIANCE? Innov Aging 2017. [DOI: 10.1093/geroni/igx004.1783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- N. Zheng
- RTI International, Waltham, Massachusetts
| | - N. Sherif
- RTI International, Waltham, Massachusetts
| | - Q. Li
- RTI International, Waltham, Massachusetts
| | - I. Broyles
- RTI International, Waltham, Massachusetts
| | - N. Chong
- RTI International, Waltham, Massachusetts
| | - J. Frank
- RTI International, Waltham, Massachusetts
| | - F. Rokoske
- RTI International, Waltham, Massachusetts
| |
Collapse
|
38
|
Witt SH, Streit F, Jungkunz M, Frank J, Awasthi S, Reinbold CS, Treutlein J, Degenhardt F, Forstner AJ, Heilmann-Heimbach S, Dietl L, Schwarze CE, Schendel D, Strohmaier J, Abdellaoui A, Adolfsson R, Air TM, Akil H, Alda M, Alliey-Rodriguez N, Andreassen OA, Babadjanova G, Bass NJ, Bauer M, Baune BT, Bellivier F, Bergen S, Bethell A, Biernacka JM, Blackwood DHR, Boks MP, Boomsma DI, Børglum AD, Borrmann-Hassenbach M, Brennan P, Budde M, Buttenschøn HN, Byrne EM, Cervantes P, Clarke TK, Craddock N, Cruceanu C, Curtis D, Czerski PM, Dannlowski U, Davis T, de Geus EJC, Di Florio A, Djurovic S, Domenici E, Edenberg HJ, Etain B, Fischer SB, Forty L, Fraser C, Frye MA, Fullerton JM, Gade K, Gershon ES, Giegling I, Gordon SD, Gordon-Smith K, Grabe HJ, Green EK, Greenwood TA, Grigoroiu-Serbanescu M, Guzman-Parra J, Hall LS, Hamshere M, Hauser J, Hautzinger M, Heilbronner U, Herms S, Hitturlingappa S, Hoffmann P, Holmans P, Hottenga JJ, Jamain S, Jones I, Jones LA, Juréus A, Kahn RS, Kammerer-Ciernioch J, Kirov G, Kittel-Schneider S, Kloiber S, Knott SV, Kogevinas M, Landén M, Leber M, Leboyer M, Li QS, Lissowska J, Lucae S, Martin NG, Mayoral-Cleries F, McElroy SL, McIntosh AM, McKay JD, McQuillin A, Medland SE, Middeldorp CM, Milaneschi Y, Mitchell PB, Montgomery GW, Morken G, Mors O, Mühleisen TW, Müller-Myhsok B, Myers RM, Nievergelt CM, Nurnberger JI, O'Donovan MC, Loohuis LMO, Ophoff R, Oruc L, Owen MJ, Paciga SA, Penninx BWJH, Perry A, Pfennig A, Potash JB, Preisig M, Reif A, Rivas F, Rouleau GA, Schofield PR, Schulze TG, Schwarz M, Scott L, Sinnamon GCB, Stahl EA, Strauss J, Turecki G, Van der Auwera S, Vedder H, Vincent JB, Willemsen G, Witt CC, Wray NR, Xi HS, Tadic A, Dahmen N, Schott BH, Cichon S, Nöthen MM, Ripke S, Mobascher A, Rujescu D, Lieb K, Roepke S, Schmahl C, Bohus M, Rietschel M. Genome-wide association study of borderline personality disorder reveals genetic overlap with bipolar disorder, major depression and schizophrenia. Transl Psychiatry 2017; 7:e1155. [PMID: 28632202 PMCID: PMC5537640 DOI: 10.1038/tp.2017.115] [Citation(s) in RCA: 95] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Accepted: 04/10/2017] [Indexed: 01/02/2023] Open
Abstract
Borderline personality disorder (BOR) is determined by environmental and genetic factors, and characterized by affective instability and impulsivity, diagnostic symptoms also observed in manic phases of bipolar disorder (BIP). Up to 20% of BIP patients show comorbidity with BOR. This report describes the first case-control genome-wide association study (GWAS) of BOR, performed in one of the largest BOR patient samples worldwide. The focus of our analysis was (i) to detect genes and gene sets involved in BOR and (ii) to investigate the genetic overlap with BIP. As there is considerable genetic overlap between BIP, major depression (MDD) and schizophrenia (SCZ) and a high comorbidity of BOR and MDD, we also analyzed the genetic overlap of BOR with SCZ and MDD. GWAS, gene-based tests and gene-set analyses were performed in 998 BOR patients and 1545 controls. Linkage disequilibrium score regression was used to detect the genetic overlap between BOR and these disorders. Single marker analysis revealed no significant association after correction for multiple testing. Gene-based analysis yielded two significant genes: DPYD (P=4.42 × 10-7) and PKP4 (P=8.67 × 10-7); and gene-set analysis yielded a significant finding for exocytosis (GO:0006887, PFDR=0.019; FDR, false discovery rate). Prior studies have implicated DPYD, PKP4 and exocytosis in BIP and SCZ. The most notable finding of the present study was the genetic overlap of BOR with BIP (rg=0.28 [P=2.99 × 10-3]), SCZ (rg=0.34 [P=4.37 × 10-5]) and MDD (rg=0.57 [P=1.04 × 10-3]). We believe our study is the first to demonstrate that BOR overlaps with BIP, MDD and SCZ on the genetic level. Whether this is confined to transdiagnostic clinical symptoms should be examined in future studies.
Collapse
Affiliation(s)
- S H Witt
- Central Institute of Mental Health, Department of Genetic Epidemiology in Psychiatry, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - F Streit
- Central Institute of Mental Health, Department of Genetic Epidemiology in Psychiatry, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - M Jungkunz
- Central Institute of Mental Health, Clinic of Psychosomatic and Psychotherapeutic Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- Central Institute of Mental Health, Institute for Psychiatric and Psychosomatic Psychotherapy (IPPP)/Psychosomatic Medicine and Psychotherapy, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - J Frank
- Central Institute of Mental Health, Department of Genetic Epidemiology in Psychiatry, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - S Awasthi
- Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
| | - C S Reinbold
- Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland
| | - J Treutlein
- Central Institute of Mental Health, Department of Genetic Epidemiology in Psychiatry, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - F Degenhardt
- Institute of Human Genetics, University of Bonn, Bonn, Germany
- Life and Brain Center, Department of Genomics, University of Bonn, Bonn, Germany
| | - A J Forstner
- Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland
- Institute of Human Genetics, University of Bonn, Bonn, Germany
- Life and Brain Center, Department of Genomics, University of Bonn, Bonn, Germany
- Department of Psychiatry (UPK), University of Basel, Basel, Switzerland
| | | | - L Dietl
- Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
| | - C E Schwarze
- Department of Clinical Psychology and Psychotherapy, University of Heidelberg, Heidelberg, Germany
| | - D Schendel
- Central Institute of Mental Health, Department of Genetic Epidemiology in Psychiatry, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - J Strohmaier
- Central Institute of Mental Health, Department of Genetic Epidemiology in Psychiatry, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - A Abdellaoui
- Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - R Adolfsson
- Department of Clinical Sciences, Psychiatry, Umeå University, Umeå, Sweden
| | - T M Air
- Discipline of Psychiatry, University of Adelaide, Adelaide, SA, Australia
| | - H Akil
- Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, USA
| | - M Alda
- Department of Psychiatry, Dalhousie University, Halifax, NS, Canada
| | - N Alliey-Rodriguez
- Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA
| | - O A Andreassen
- Division Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
- NORMENT, University of Oslo, Oslo, Norway
| | - G Babadjanova
- Institute of Pulmonology, Russian State Medical University, Moscow, Russian Federation
| | - N J Bass
- Division of Psychiatry, University College London, London, UK
| | - M Bauer
- Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Dresden, Germany
| | - B T Baune
- Discipline of Psychiatry, University of Adelaide, Adelaide, SA, Australia
| | - F Bellivier
- Inserm, U1144, AP-HP, GH Saint-Louis, Département de Psychiatrie et de Médecine Addictologique, Paris, France
| | - S Bergen
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - A Bethell
- National Center for Mental Health, Cardiff University, Cardiff, UK
| | - J M Biernacka
- Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | - D H R Blackwood
- Division of Psychiatry, University of Edinburgh, Edinburgh, UK
| | - M P Boks
- Urain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands
| | - D I Boomsma
- Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - A D Børglum
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
- iSEQ, Centre for Integrative Sequencing, Aarhus University, Aarhus, Denmark
- iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark
| | | | - P Brennan
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| | - M Budde
- Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Goettingen, Germany
- Medical Center of the University of Munich, Campus Innenstadt, Institute of Psychiatric Phenomics and Genomics (IPPG), Munich, Germany
| | - H N Buttenschøn
- Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| | - E M Byrne
- Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia
| | - P Cervantes
- Department of Psychiatry, McGill University, Montreal, QC, Canada
| | - T-K Clarke
- Division of Psychiatry, University of Edinburgh, Edinburgh, UK
| | - N Craddock
- Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
| | - C Cruceanu
- Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany
| | - D Curtis
- Centre for Psychiatry, Queen Mary University of London, London, UK
- UCL Genetics Institute, University College London, London, UK
| | - P M Czerski
- Laboratory of Psychiatric Genetics, Department of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
| | - U Dannlowski
- Department of Psychiatry, University of Marburg, Marburg, Germany
- Department of Psychiatry, University of Münste, Münster, Germany
| | - T Davis
- Discipline of Psychiatry, University of Adelaide, Adelaide, SA, Australia
| | - E J C de Geus
- Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - A Di Florio
- Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
| | - S Djurovic
- Department of Medical Genetics, Oslo University Hospital Ullevål, Oslo, Norway
- NORMENT, KG Jebsen Centre for Psychosis Research, Department of Clinical Science, University of Bergen, Bergen, Norway
| | - E Domenici
- Centre for Integrative Biology, Università degli Studi di Trento, Trento, Italy
| | - H J Edenberg
- Indiana University School of Medicine, Department of Biochemistry and Molecular Biology, Indianapolis, IN, USA
- Indiana University School of Medicine, Department of Medical and Molecular Genetics, Indianapolis, IN, USA
| | - B Etain
- Faculté de Médecine, Université Paris Est, Créteil, France
| | - S B Fischer
- Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland
| | - L Forty
- Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
| | - C Fraser
- Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
| | - M A Frye
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
| | - J M Fullerton
- School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
- Neuroscience Research Australia, Sydney, NSW, Australia
| | - K Gade
- Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Goettingen, Germany
- Medical Center of the University of Munich, Campus Innenstadt, Institute of Psychiatric Phenomics and Genomics (IPPG), Munich, Germany
| | - E S Gershon
- Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA
| | - I Giegling
- Department of Psychiatry, University of Halle, Halle, Germany
| | - S D Gordon
- Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - K Gordon-Smith
- Department of Psychological Medicine, University of Worcester, Worcester, UK
| | - H J Grabe
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany
| | - E K Green
- School of Biomedical and Healthcare Sciences, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK
| | - T A Greenwood
- Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
| | - M Grigoroiu-Serbanescu
- Biometric Psychiatric Genetics Research Unit, Alexandru Obregia Clinical Psychiatric Hospital, Bucharest, Romania
| | - J Guzman-Parra
- Mental Health Department, Biomedicine Institute, University Regional Hospital, Málaga, Spain
| | - L S Hall
- Division of Psychiatry, University of Edinburgh, Edinburgh, UK
- Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
| | - M Hamshere
- Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
| | - J Hauser
- Laboratory of Psychiatric Genetics, Department of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
| | - M Hautzinger
- Department of Psychology, Eberhard Karls Universität Tübingen, Tubingen, Germany
| | - U Heilbronner
- Medical Center of the University of Munich, Campus Innenstadt, Institute of Psychiatric Phenomics and Genomics (IPPG), Munich, Germany
| | - S Herms
- Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland
- Institute of Human Genetics, University of Bonn, Bonn, Germany
- Life and Brain Center, Department of Genomics, University of Bonn, Bonn, Germany
| | - S Hitturlingappa
- Discipline of Psychiatry, University of Adelaide, Adelaide, SA, Australia
| | - P Hoffmann
- Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland
- Institute of Human Genetics, University of Bonn, Bonn, Germany
- Life and Brain Center, Department of Genomics, University of Bonn, Bonn, Germany
| | - P Holmans
- Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
| | - J-J Hottenga
- Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - S Jamain
- Faculté de Médecine, Université Paris Est, Créteil, France
- Inserm U955, Psychiatrie Translationnelle, Créteil, France
| | - I Jones
- National Center for Mental Health, Cardiff University, Cardiff, UK
| | - L A Jones
- Department of Psychological Medicine, University of Worcester, Worcester, UK
| | - A Juréus
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - R S Kahn
- University Medical Center Utrecht, Division of Neuroscience, Department of Psychiatry, Utrecht, The Netherlands
| | | | - G Kirov
- Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
| | - S Kittel-Schneider
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt am Main, Frankfurt am Main, Germany
| | - S Kloiber
- Centre for Addiction and Mental Health, Toronto, ON, Canada
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Max Planck Institute of Psychiatry, Munich, Germany
| | - S V Knott
- Department of Psychological Medicine, University of Worcester, Worcester, UK
| | - M Kogevinas
- Center for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
| | - M Landén
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
| | - M Leber
- Clinic for Psychiatry and Psychotherapy, University Hospital Cologne, Cologne, Germany
| | - M Leboyer
- Inserm U955, Translational Psychiatry Laboratory, AP-HP, DHU PePSY, Department of Psychiatry, Université Paris Est, Créteil, France
| | - Q S Li
- Janssen Research and Development, LLC, Neuroscience Therapeutic Area, Titusville, NJ, USA
| | - J Lissowska
- M. Sklodowska-Curie Cancer Center and Institute of Oncology, Cancer Epidemiology and Prevention, Warsaw, Poland
| | - S Lucae
- Max Planck Institute of Psychiatry, Munich, Germany
| | - N G Martin
- Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
- School of Psychology, The University of Queensland, Brisbane, QLD, Australia
| | - F Mayoral-Cleries
- Mental Health Department, Biomedicine Institute, University Regional Hospital, Málaga, Spain
| | - S L McElroy
- Lindner Center of HOPE, Research Institute, Mason, OH, USA
| | - A M McIntosh
- Division of Psychiatry, University of Edinburgh, Edinburgh, UK
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK
| | - J D McKay
- Genetic Cancer Susceptibility Group, International Agency for Research on Cancer, Lyon, France
| | - A McQuillin
- Division of Psychiatry, University College London, London, UK
| | - S E Medland
- Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - C M Middeldorp
- Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Y Milaneschi
- VU University Medical Center and GGZ inGeest, Department of Psychiatry, Amsterdam, The Netherlands
| | - P B Mitchell
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia
- Black Dog Institute, Sydney, NSW, Australia
| | - G W Montgomery
- Institute for Molecular Biology, University of Queensland, Brisbane, QLD, Australia
| | - G Morken
- Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
- Department of Psychiatry, St Olavs University Hospital, Trondheim, Norway
| | - O Mors
- Risskov, Psychosis Research Unit, Aarhus University Hospital, Aarhus, Denmark
- iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| | - T W Mühleisen
- Research Center Juelich, Institute of Neuroscience and Medicine (INM-1), Juelich, Germany
- Division of Medical Genetics, University of Basel, Basel, Switzerland
| | - B Müller-Myhsok
- Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
- University of Liverpool, Liverpool, UK
| | - R M Myers
- HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA
| | - C M Nievergelt
- Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
| | - J I Nurnberger
- Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA
| | - M C O'Donovan
- MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK
| | - L M O Loohuis
- Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, CA, USA
| | - R Ophoff
- University Medical Center Utrecht, Division of Brain Research, Utrecht, The Netherlands
| | - L Oruc
- Psychiatry Clinic, Clinical Center University of Sarajevo, Sarajevo, Bosnia-Herzegovina
| | - M J Owen
- MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK
| | - S A Paciga
- Pfizer Global Research and Development, Human Genetics and Computational Biomedicine, Groton, CT, USA
| | - B W J H Penninx
- VU University Medical Center and GGZ inGeest, Department of Psychiatry, Amsterdam, The Netherlands
| | - A Perry
- Department of Psychological Medicine, University of Worcester, Worcester, UK
| | - A Pfennig
- Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Dresden, Germany
| | - J B Potash
- Department of Psychiatry, University of Iowa, Iowa City, IA, USA
| | - M Preisig
- Department of Psychiatry, Psychiatric University Hospital of Lausanne, Lausanne, Switzerland
| | - A Reif
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt am Main, Frankfurt am Main, Germany
| | - F Rivas
- Mental Health Department, Biomedicine Institute, University Regional Hospital, Málaga, Spain
| | - G A Rouleau
- Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute and Hospital, Montreal, QC, Canada
| | - P R Schofield
- School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
- Neuroscience Research Australia, Sydney, NSW, Australia
| | - T G Schulze
- Central Institute of Mental Health, Department of Genetic Epidemiology in Psychiatry, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Goettingen, Germany
- Medical Center of the University of Munich, Campus Innenstadt, Institute of Psychiatric Phenomics and Genomics (IPPG), Munich, Germany
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA
- NIMH Division of Intramural Research Programs, Human Genetics Branch, Bethesda, MD, USA
| | - M Schwarz
- Psychiatric Center Nordbaden, Wiesloch, Germany
| | - L Scott
- Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
| | - G C B Sinnamon
- School of Medicine and Dentistry, James Cook University, Townsville, QLD, Australia
| | - E A Stahl
- Broad Institute of MIT and Harvard, Medical and Population Genetics, Cambridge, MA, USA
- Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - J Strauss
- Centre for Addiction and Mental Health, Toronto, ON, Canada
| | - G Turecki
- Department of Psychiatry, McGill University, Montreal, QC, Canada
| | - S Van der Auwera
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany
| | - H Vedder
- Psychiatric Center Nordbaden, Wiesloch, Germany
| | - J B Vincent
- Centre for Addiction and Mental Health, Molecular Neuropsychiatry and Development Laboratory, Toronto, ON, Canada
| | - G Willemsen
- Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - C C Witt
- Department of Anaesthesiology and Operative Intensive Care, University Hospital Mannheim, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany
| | - N R Wray
- Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia
| | - H S Xi
- Pfizer Global Research and Development, Computational Sciences Center of Emphasis, Cambridge, MA, USA
| | - Bipolar Disorders Working Group of the Psychiatric Genomics Consortium
- Central Institute of Mental Health, Department of Genetic Epidemiology in Psychiatry, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- Central Institute of Mental Health, Clinic of Psychosomatic and Psychotherapeutic Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- Central Institute of Mental Health, Institute for Psychiatric and Psychosomatic Psychotherapy (IPPP)/Psychosomatic Medicine and Psychotherapy, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
- Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland
- Institute of Human Genetics, University of Bonn, Bonn, Germany
- Life and Brain Center, Department of Genomics, University of Bonn, Bonn, Germany
- Department of Psychiatry (UPK), University of Basel, Basel, Switzerland
- Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
- Department of Clinical Psychology and Psychotherapy, University of Heidelberg, Heidelberg, Germany
- Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- Department of Clinical Sciences, Psychiatry, Umeå University, Umeå, Sweden
- Discipline of Psychiatry, University of Adelaide, Adelaide, SA, Australia
- Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, USA
- Department of Psychiatry, Dalhousie University, Halifax, NS, Canada
- Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA
- Division Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
- NORMENT, University of Oslo, Oslo, Norway
- Institute of Pulmonology, Russian State Medical University, Moscow, Russian Federation
- Division of Psychiatry, University College London, London, UK
- Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Dresden, Germany
- Inserm, U1144, AP-HP, GH Saint-Louis, Département de Psychiatrie et de Médecine Addictologique, Paris, France
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- National Center for Mental Health, Cardiff University, Cardiff, UK
- Health Sciences Research, Mayo Clinic, Rochester, MN, USA
- Division of Psychiatry, University of Edinburgh, Edinburgh, UK
- Urain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
- iSEQ, Centre for Integrative Sequencing, Aarhus University, Aarhus, Denmark
- iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark
- Medical and Quality Assurance, Clinics of Upper Bavaria, Munich, Germany
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
- Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Goettingen, Germany
- Medical Center of the University of Munich, Campus Innenstadt, Institute of Psychiatric Phenomics and Genomics (IPPG), Munich, Germany
- Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
- Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia
- Department of Psychiatry, McGill University, Montreal, QC, Canada
- Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
- Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany
- Centre for Psychiatry, Queen Mary University of London, London, UK
- UCL Genetics Institute, University College London, London, UK
- Laboratory of Psychiatric Genetics, Department of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
- Department of Psychiatry, University of Marburg, Marburg, Germany
- Department of Psychiatry, University of Münste, Münster, Germany
- Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
- Department of Medical Genetics, Oslo University Hospital Ullevål, Oslo, Norway
- NORMENT, KG Jebsen Centre for Psychosis Research, Department of Clinical Science, University of Bergen, Bergen, Norway
- Centre for Integrative Biology, Università degli Studi di Trento, Trento, Italy
- Indiana University School of Medicine, Department of Biochemistry and Molecular Biology, Indianapolis, IN, USA
- Indiana University School of Medicine, Department of Medical and Molecular Genetics, Indianapolis, IN, USA
- Faculté de Médecine, Université Paris Est, Créteil, France
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
- School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
- Neuroscience Research Australia, Sydney, NSW, Australia
- Department of Psychiatry, University of Halle, Halle, Germany
- Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
- Department of Psychological Medicine, University of Worcester, Worcester, UK
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany
- School of Biomedical and Healthcare Sciences, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK
- Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
- Biometric Psychiatric Genetics Research Unit, Alexandru Obregia Clinical Psychiatric Hospital, Bucharest, Romania
- Mental Health Department, Biomedicine Institute, University Regional Hospital, Málaga, Spain
- Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
- Department of Psychology, Eberhard Karls Universität Tübingen, Tubingen, Germany
- Inserm U955, Psychiatrie Translationnelle, Créteil, France
- University Medical Center Utrecht, Division of Neuroscience, Department of Psychiatry, Utrecht, The Netherlands
- Center of Psychiatry Weinsberg, Weinsberg, Germany
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt am Main, Frankfurt am Main, Germany
- Centre for Addiction and Mental Health, Toronto, ON, Canada
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Max Planck Institute of Psychiatry, Munich, Germany
- Center for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
- Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
- Clinic for Psychiatry and Psychotherapy, University Hospital Cologne, Cologne, Germany
- Inserm U955, Translational Psychiatry Laboratory, AP-HP, DHU PePSY, Department of Psychiatry, Université Paris Est, Créteil, France
- Janssen Research and Development, LLC, Neuroscience Therapeutic Area, Titusville, NJ, USA
- M. Sklodowska-Curie Cancer Center and Institute of Oncology, Cancer Epidemiology and Prevention, Warsaw, Poland
- School of Psychology, The University of Queensland, Brisbane, QLD, Australia
- Lindner Center of HOPE, Research Institute, Mason, OH, USA
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK
- Genetic Cancer Susceptibility Group, International Agency for Research on Cancer, Lyon, France
- Division of Psychiatry, University College London, London, UK
- VU University Medical Center and GGZ inGeest, Department of Psychiatry, Amsterdam, The Netherlands
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia
- Black Dog Institute, Sydney, NSW, Australia
- Institute for Molecular Biology, University of Queensland, Brisbane, QLD, Australia
- Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
- Department of Psychiatry, St Olavs University Hospital, Trondheim, Norway
- Risskov, Psychosis Research Unit, Aarhus University Hospital, Aarhus, Denmark
- iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
- Research Center Juelich, Institute of Neuroscience and Medicine (INM-1), Juelich, Germany
- Division of Medical Genetics, University of Basel, Basel, Switzerland
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
- University of Liverpool, Liverpool, UK
- HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA
- Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA
- MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK
- Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, CA, USA
- University Medical Center Utrecht, Division of Brain Research, Utrecht, The Netherlands
- Psychiatry Clinic, Clinical Center University of Sarajevo, Sarajevo, Bosnia-Herzegovina
- Pfizer Global Research and Development, Human Genetics and Computational Biomedicine, Groton, CT, USA
- Department of Psychiatry, University of Iowa, Iowa City, IA, USA
- Department of Psychiatry, Psychiatric University Hospital of Lausanne, Lausanne, Switzerland
- Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute and Hospital, Montreal, QC, Canada
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA
- NIMH Division of Intramural Research Programs, Human Genetics Branch, Bethesda, MD, USA
- Psychiatric Center Nordbaden, Wiesloch, Germany
- Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
- School of Medicine and Dentistry, James Cook University, Townsville, QLD, Australia
- Broad Institute of MIT and Harvard, Medical and Population Genetics, Cambridge, MA, USA
- Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Centre for Addiction and Mental Health, Molecular Neuropsychiatry and Development Laboratory, Toronto, ON, Canada
- Department of Anaesthesiology and Operative Intensive Care, University Hospital Mannheim, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia
- Pfizer Global Research and Development, Computational Sciences Center of Emphasis, Cambridge, MA, USA
- AGAPLESION Elisabethenstift gGmbh, Department of Psychiatry, Psychosomatics and Psychotherapy, Darmstadt, Germany
- University Medical Center, Department of Psychiatry and Psychotherapy, Mainz, Germany
- Leibniz Institute for Neurobiology, Magdeburg, Germany
- Department of Biomedicine, University of Basel, Basel, Switzerland
- Stanley Center for Psychiatric Research and Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Analytic and Translational Genetics Unit, Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA
| | - Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium
- Central Institute of Mental Health, Department of Genetic Epidemiology in Psychiatry, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- Central Institute of Mental Health, Clinic of Psychosomatic and Psychotherapeutic Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- Central Institute of Mental Health, Institute for Psychiatric and Psychosomatic Psychotherapy (IPPP)/Psychosomatic Medicine and Psychotherapy, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
- Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland
- Institute of Human Genetics, University of Bonn, Bonn, Germany
- Life and Brain Center, Department of Genomics, University of Bonn, Bonn, Germany
- Department of Psychiatry (UPK), University of Basel, Basel, Switzerland
- Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
- Department of Clinical Psychology and Psychotherapy, University of Heidelberg, Heidelberg, Germany
- Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- Department of Clinical Sciences, Psychiatry, Umeå University, Umeå, Sweden
- Discipline of Psychiatry, University of Adelaide, Adelaide, SA, Australia
- Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, USA
- Department of Psychiatry, Dalhousie University, Halifax, NS, Canada
- Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA
- Division Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
- NORMENT, University of Oslo, Oslo, Norway
- Institute of Pulmonology, Russian State Medical University, Moscow, Russian Federation
- Division of Psychiatry, University College London, London, UK
- Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Dresden, Germany
- Inserm, U1144, AP-HP, GH Saint-Louis, Département de Psychiatrie et de Médecine Addictologique, Paris, France
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- National Center for Mental Health, Cardiff University, Cardiff, UK
- Health Sciences Research, Mayo Clinic, Rochester, MN, USA
- Division of Psychiatry, University of Edinburgh, Edinburgh, UK
- Urain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
- iSEQ, Centre for Integrative Sequencing, Aarhus University, Aarhus, Denmark
- iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark
- Medical and Quality Assurance, Clinics of Upper Bavaria, Munich, Germany
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
- Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Goettingen, Germany
- Medical Center of the University of Munich, Campus Innenstadt, Institute of Psychiatric Phenomics and Genomics (IPPG), Munich, Germany
- Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
- Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia
- Department of Psychiatry, McGill University, Montreal, QC, Canada
- Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
- Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany
- Centre for Psychiatry, Queen Mary University of London, London, UK
- UCL Genetics Institute, University College London, London, UK
- Laboratory of Psychiatric Genetics, Department of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
- Department of Psychiatry, University of Marburg, Marburg, Germany
- Department of Psychiatry, University of Münste, Münster, Germany
- Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
- Department of Medical Genetics, Oslo University Hospital Ullevål, Oslo, Norway
- NORMENT, KG Jebsen Centre for Psychosis Research, Department of Clinical Science, University of Bergen, Bergen, Norway
- Centre for Integrative Biology, Università degli Studi di Trento, Trento, Italy
- Indiana University School of Medicine, Department of Biochemistry and Molecular Biology, Indianapolis, IN, USA
- Indiana University School of Medicine, Department of Medical and Molecular Genetics, Indianapolis, IN, USA
- Faculté de Médecine, Université Paris Est, Créteil, France
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
- School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
- Neuroscience Research Australia, Sydney, NSW, Australia
- Department of Psychiatry, University of Halle, Halle, Germany
- Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
- Department of Psychological Medicine, University of Worcester, Worcester, UK
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany
- School of Biomedical and Healthcare Sciences, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK
- Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
- Biometric Psychiatric Genetics Research Unit, Alexandru Obregia Clinical Psychiatric Hospital, Bucharest, Romania
- Mental Health Department, Biomedicine Institute, University Regional Hospital, Málaga, Spain
- Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
- Department of Psychology, Eberhard Karls Universität Tübingen, Tubingen, Germany
- Inserm U955, Psychiatrie Translationnelle, Créteil, France
- University Medical Center Utrecht, Division of Neuroscience, Department of Psychiatry, Utrecht, The Netherlands
- Center of Psychiatry Weinsberg, Weinsberg, Germany
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt am Main, Frankfurt am Main, Germany
- Centre for Addiction and Mental Health, Toronto, ON, Canada
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Max Planck Institute of Psychiatry, Munich, Germany
- Center for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
- Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
- Clinic for Psychiatry and Psychotherapy, University Hospital Cologne, Cologne, Germany
- Inserm U955, Translational Psychiatry Laboratory, AP-HP, DHU PePSY, Department of Psychiatry, Université Paris Est, Créteil, France
- Janssen Research and Development, LLC, Neuroscience Therapeutic Area, Titusville, NJ, USA
- M. Sklodowska-Curie Cancer Center and Institute of Oncology, Cancer Epidemiology and Prevention, Warsaw, Poland
- School of Psychology, The University of Queensland, Brisbane, QLD, Australia
- Lindner Center of HOPE, Research Institute, Mason, OH, USA
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK
- Genetic Cancer Susceptibility Group, International Agency for Research on Cancer, Lyon, France
- Division of Psychiatry, University College London, London, UK
- VU University Medical Center and GGZ inGeest, Department of Psychiatry, Amsterdam, The Netherlands
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia
- Black Dog Institute, Sydney, NSW, Australia
- Institute for Molecular Biology, University of Queensland, Brisbane, QLD, Australia
- Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
- Department of Psychiatry, St Olavs University Hospital, Trondheim, Norway
- Risskov, Psychosis Research Unit, Aarhus University Hospital, Aarhus, Denmark
- iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
- Research Center Juelich, Institute of Neuroscience and Medicine (INM-1), Juelich, Germany
- Division of Medical Genetics, University of Basel, Basel, Switzerland
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
- University of Liverpool, Liverpool, UK
- HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA
- Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA
- MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK
- Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, CA, USA
- University Medical Center Utrecht, Division of Brain Research, Utrecht, The Netherlands
- Psychiatry Clinic, Clinical Center University of Sarajevo, Sarajevo, Bosnia-Herzegovina
- Pfizer Global Research and Development, Human Genetics and Computational Biomedicine, Groton, CT, USA
- Department of Psychiatry, University of Iowa, Iowa City, IA, USA
- Department of Psychiatry, Psychiatric University Hospital of Lausanne, Lausanne, Switzerland
- Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute and Hospital, Montreal, QC, Canada
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA
- NIMH Division of Intramural Research Programs, Human Genetics Branch, Bethesda, MD, USA
- Psychiatric Center Nordbaden, Wiesloch, Germany
- Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
- School of Medicine and Dentistry, James Cook University, Townsville, QLD, Australia
- Broad Institute of MIT and Harvard, Medical and Population Genetics, Cambridge, MA, USA
- Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Centre for Addiction and Mental Health, Molecular Neuropsychiatry and Development Laboratory, Toronto, ON, Canada
- Department of Anaesthesiology and Operative Intensive Care, University Hospital Mannheim, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia
- Pfizer Global Research and Development, Computational Sciences Center of Emphasis, Cambridge, MA, USA
- AGAPLESION Elisabethenstift gGmbh, Department of Psychiatry, Psychosomatics and Psychotherapy, Darmstadt, Germany
- University Medical Center, Department of Psychiatry and Psychotherapy, Mainz, Germany
- Leibniz Institute for Neurobiology, Magdeburg, Germany
- Department of Biomedicine, University of Basel, Basel, Switzerland
- Stanley Center for Psychiatric Research and Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Analytic and Translational Genetics Unit, Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA
| | - Schizophrenia Working Group of the Psychiatric Genomics Consortium
- Central Institute of Mental Health, Department of Genetic Epidemiology in Psychiatry, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- Central Institute of Mental Health, Clinic of Psychosomatic and Psychotherapeutic Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- Central Institute of Mental Health, Institute for Psychiatric and Psychosomatic Psychotherapy (IPPP)/Psychosomatic Medicine and Psychotherapy, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
- Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland
- Institute of Human Genetics, University of Bonn, Bonn, Germany
- Life and Brain Center, Department of Genomics, University of Bonn, Bonn, Germany
- Department of Psychiatry (UPK), University of Basel, Basel, Switzerland
- Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
- Department of Clinical Psychology and Psychotherapy, University of Heidelberg, Heidelberg, Germany
- Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- Department of Clinical Sciences, Psychiatry, Umeå University, Umeå, Sweden
- Discipline of Psychiatry, University of Adelaide, Adelaide, SA, Australia
- Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, USA
- Department of Psychiatry, Dalhousie University, Halifax, NS, Canada
- Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA
- Division Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
- NORMENT, University of Oslo, Oslo, Norway
- Institute of Pulmonology, Russian State Medical University, Moscow, Russian Federation
- Division of Psychiatry, University College London, London, UK
- Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Dresden, Germany
- Inserm, U1144, AP-HP, GH Saint-Louis, Département de Psychiatrie et de Médecine Addictologique, Paris, France
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- National Center for Mental Health, Cardiff University, Cardiff, UK
- Health Sciences Research, Mayo Clinic, Rochester, MN, USA
- Division of Psychiatry, University of Edinburgh, Edinburgh, UK
- Urain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
- iSEQ, Centre for Integrative Sequencing, Aarhus University, Aarhus, Denmark
- iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark
- Medical and Quality Assurance, Clinics of Upper Bavaria, Munich, Germany
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
- Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Goettingen, Germany
- Medical Center of the University of Munich, Campus Innenstadt, Institute of Psychiatric Phenomics and Genomics (IPPG), Munich, Germany
- Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
- Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia
- Department of Psychiatry, McGill University, Montreal, QC, Canada
- Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
- Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany
- Centre for Psychiatry, Queen Mary University of London, London, UK
- UCL Genetics Institute, University College London, London, UK
- Laboratory of Psychiatric Genetics, Department of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
- Department of Psychiatry, University of Marburg, Marburg, Germany
- Department of Psychiatry, University of Münste, Münster, Germany
- Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
- Department of Medical Genetics, Oslo University Hospital Ullevål, Oslo, Norway
- NORMENT, KG Jebsen Centre for Psychosis Research, Department of Clinical Science, University of Bergen, Bergen, Norway
- Centre for Integrative Biology, Università degli Studi di Trento, Trento, Italy
- Indiana University School of Medicine, Department of Biochemistry and Molecular Biology, Indianapolis, IN, USA
- Indiana University School of Medicine, Department of Medical and Molecular Genetics, Indianapolis, IN, USA
- Faculté de Médecine, Université Paris Est, Créteil, France
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
- School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
- Neuroscience Research Australia, Sydney, NSW, Australia
- Department of Psychiatry, University of Halle, Halle, Germany
- Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
- Department of Psychological Medicine, University of Worcester, Worcester, UK
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany
- School of Biomedical and Healthcare Sciences, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK
- Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
- Biometric Psychiatric Genetics Research Unit, Alexandru Obregia Clinical Psychiatric Hospital, Bucharest, Romania
- Mental Health Department, Biomedicine Institute, University Regional Hospital, Málaga, Spain
- Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
- Department of Psychology, Eberhard Karls Universität Tübingen, Tubingen, Germany
- Inserm U955, Psychiatrie Translationnelle, Créteil, France
- University Medical Center Utrecht, Division of Neuroscience, Department of Psychiatry, Utrecht, The Netherlands
- Center of Psychiatry Weinsberg, Weinsberg, Germany
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt am Main, Frankfurt am Main, Germany
- Centre for Addiction and Mental Health, Toronto, ON, Canada
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Max Planck Institute of Psychiatry, Munich, Germany
- Center for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
- Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
- Clinic for Psychiatry and Psychotherapy, University Hospital Cologne, Cologne, Germany
- Inserm U955, Translational Psychiatry Laboratory, AP-HP, DHU PePSY, Department of Psychiatry, Université Paris Est, Créteil, France
- Janssen Research and Development, LLC, Neuroscience Therapeutic Area, Titusville, NJ, USA
- M. Sklodowska-Curie Cancer Center and Institute of Oncology, Cancer Epidemiology and Prevention, Warsaw, Poland
- School of Psychology, The University of Queensland, Brisbane, QLD, Australia
- Lindner Center of HOPE, Research Institute, Mason, OH, USA
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK
- Genetic Cancer Susceptibility Group, International Agency for Research on Cancer, Lyon, France
- Division of Psychiatry, University College London, London, UK
- VU University Medical Center and GGZ inGeest, Department of Psychiatry, Amsterdam, The Netherlands
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia
- Black Dog Institute, Sydney, NSW, Australia
- Institute for Molecular Biology, University of Queensland, Brisbane, QLD, Australia
- Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
- Department of Psychiatry, St Olavs University Hospital, Trondheim, Norway
- Risskov, Psychosis Research Unit, Aarhus University Hospital, Aarhus, Denmark
- iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
- Research Center Juelich, Institute of Neuroscience and Medicine (INM-1), Juelich, Germany
- Division of Medical Genetics, University of Basel, Basel, Switzerland
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
- University of Liverpool, Liverpool, UK
- HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA
- Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA
- MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK
- Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, CA, USA
- University Medical Center Utrecht, Division of Brain Research, Utrecht, The Netherlands
- Psychiatry Clinic, Clinical Center University of Sarajevo, Sarajevo, Bosnia-Herzegovina
- Pfizer Global Research and Development, Human Genetics and Computational Biomedicine, Groton, CT, USA
- Department of Psychiatry, University of Iowa, Iowa City, IA, USA
- Department of Psychiatry, Psychiatric University Hospital of Lausanne, Lausanne, Switzerland
- Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute and Hospital, Montreal, QC, Canada
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA
- NIMH Division of Intramural Research Programs, Human Genetics Branch, Bethesda, MD, USA
- Psychiatric Center Nordbaden, Wiesloch, Germany
- Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
- School of Medicine and Dentistry, James Cook University, Townsville, QLD, Australia
- Broad Institute of MIT and Harvard, Medical and Population Genetics, Cambridge, MA, USA
- Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Centre for Addiction and Mental Health, Molecular Neuropsychiatry and Development Laboratory, Toronto, ON, Canada
- Department of Anaesthesiology and Operative Intensive Care, University Hospital Mannheim, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia
- Pfizer Global Research and Development, Computational Sciences Center of Emphasis, Cambridge, MA, USA
- AGAPLESION Elisabethenstift gGmbh, Department of Psychiatry, Psychosomatics and Psychotherapy, Darmstadt, Germany
- University Medical Center, Department of Psychiatry and Psychotherapy, Mainz, Germany
- Leibniz Institute for Neurobiology, Magdeburg, Germany
- Department of Biomedicine, University of Basel, Basel, Switzerland
- Stanley Center for Psychiatric Research and Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Analytic and Translational Genetics Unit, Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA
| | - A Tadic
- AGAPLESION Elisabethenstift gGmbh, Department of Psychiatry, Psychosomatics and Psychotherapy, Darmstadt, Germany
- University Medical Center, Department of Psychiatry and Psychotherapy, Mainz, Germany
| | - N Dahmen
- University Medical Center, Department of Psychiatry and Psychotherapy, Mainz, Germany
| | - B H Schott
- Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
- Leibniz Institute for Neurobiology, Magdeburg, Germany
| | - S Cichon
- Institute of Human Genetics, University of Bonn, Bonn, Germany
- Research Center Juelich, Institute of Neuroscience and Medicine (INM-1), Juelich, Germany
- Division of Medical Genetics, University of Basel, Basel, Switzerland
- Department of Biomedicine, University of Basel, Basel, Switzerland
| | - M M Nöthen
- Institute of Human Genetics, University of Bonn, Bonn, Germany
- Life and Brain Center, Department of Genomics, University of Bonn, Bonn, Germany
| | - S Ripke
- Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
- Stanley Center for Psychiatric Research and Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Analytic and Translational Genetics Unit, Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA
| | - A Mobascher
- University Medical Center, Department of Psychiatry and Psychotherapy, Mainz, Germany
| | - D Rujescu
- Department of Psychiatry, University of Halle, Halle, Germany
| | - K Lieb
- University Medical Center, Department of Psychiatry and Psychotherapy, Mainz, Germany
| | - S Roepke
- Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
| | - C Schmahl
- Central Institute of Mental Health, Clinic of Psychosomatic and Psychotherapeutic Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - M Bohus
- Central Institute of Mental Health, Institute for Psychiatric and Psychosomatic Psychotherapy (IPPP)/Psychosomatic Medicine and Psychotherapy, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - M Rietschel
- Central Institute of Mental Health, Department of Genetic Epidemiology in Psychiatry, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| |
Collapse
|
39
|
Lutz M, von Ingersleben N, Lambers M, Rosenberg M, Freitag-Wolf S, Dempfle A, Lutter G, Frank J, Bramlage P, Frey N, Frank D. Osteopontin predicts clinical outcome in patients after treatment of severe aortic stenosis with transcatheter aortic valve implantation (TAVI). Open Heart 2017; 4:e000633. [PMID: 28761684 PMCID: PMC5515168 DOI: 10.1136/openhrt-2017-000633] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2017] [Revised: 04/12/2017] [Accepted: 04/25/2017] [Indexed: 12/18/2022] Open
Abstract
Objective Osteopontin (OPN) is an extracellular matrix protein that plays an integral role in myocardial remodelling and has previously been shown to be a valuable biomarker in cardiovascular disease. Because of the concentric myocardial hypertrophy associated with severe, symptomatic aortic stenosis (AS), we hypothesised that OPN expression may have a prognostic value in patients undergoing transcatheter aortic valve implantation (TAVI). Methods We prospectively included 217 patients undergoing TAVI between February 2011 and December 2013 with a median follow-up of 349 days. Twenty healthy individuals from the same age range free from structural heart disease served as controls. The primary endpoint for the analysis was survival time. Results Median preprocedural OPN levels (675 ng/mL; IQR 488.5–990.5 ng/mL) were significantly higher in patients with severe aortic valve stenosis compared with healthy controls (386 ng/mL; IQR 324.5–458, p<0.001). Patients with increased OPN values showed at baseline a decreased 6 min walk test performance, increased rates of atrial arrhythmia, and an increased risk of death during follow-up (HR 2.2; 95% CI 1.3 to 3.5 for the comparison of the highest vs lowest OPN quartile). Multiple Cox regression analysis demonstrated that OPN improves the prediction of an adverse prognosis further than N-terminal probrain natriuretic peptide. Conclusions OPN levels at baseline are associated with adverse outcomes in patients with severe, symptomatic AS undergoing TAVI.
Collapse
Affiliation(s)
- Matthias Lutz
- Department of Internal Medicine III (Cardiology and Angiology), University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany.,German Centre for Cardiovascular Research, DZHK Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany
| | - Nora von Ingersleben
- Department of Internal Medicine III (Cardiology and Angiology), University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany
| | - Moritz Lambers
- Department of Internal Medicine III (Cardiology and Angiology), University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany
| | - Mark Rosenberg
- Department of Internal Medicine III (Cardiology and Angiology), University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany.,German Centre for Cardiovascular Research, DZHK Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany
| | - Sandra Freitag-Wolf
- Institute of Medical Informatics and Statistics, Christian-Albrechts University of Kiel, Kiel, Germany
| | - Astrid Dempfle
- Institute of Medical Informatics and Statistics, Christian-Albrechts University of Kiel, Kiel, Germany
| | - Georg Lutter
- German Centre for Cardiovascular Research, DZHK Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany.,Department for Cardiovascular Surgery, University Hospital Schleswig-Holstein, Kiel, Germany
| | - Johanne Frank
- Department of Internal Medicine III (Cardiology and Angiology), University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany
| | - Peter Bramlage
- Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany
| | - Norbert Frey
- Department of Internal Medicine III (Cardiology and Angiology), University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany.,German Centre for Cardiovascular Research, DZHK Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany
| | - Derk Frank
- Department of Internal Medicine III (Cardiology and Angiology), University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany.,German Centre for Cardiovascular Research, DZHK Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany
| |
Collapse
|
40
|
Leiblein M, Marzi I, Sander AL, Barker JH, Ebert F, Frank J. Necrotizing fasciitis: treatment concepts and clinical results. Eur J Trauma Emerg Surg 2017; 44:279-290. [PMID: 28484782 DOI: 10.1007/s00068-017-0792-8] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2016] [Accepted: 04/18/2017] [Indexed: 12/19/2022]
Abstract
BACKGROUND Necrotizing fasciitis is a life-threatening soft tissue infection characterized by a rapid spreading infection of the subcutaneous tissue and in particular the fascia. The management of infected tissues requires a rapid diagnosis, immediate aggressive surgical management and an extended debridement. In some cases early amputations of the affected tissues and maximum intensive care treatment, in case of sepsis, are required. Due to a rising number of cases we aimed to evaluate our patients in a retrospective review. METHOD All patients diagnosed with necrotizing fasciitis from 2014 to 2016 (21 months) in our level one trauma center were identified. Their charts were reviewed and data were analyzed in terms of demographic and social information, microbiological results, therapeutic course, socio-economic outcome and mortality. RESULTS We found 15 patients with necrotizing fasciitis. None of these died in the observation period. The mean number of surgical interventions was seven. Two patients underwent limb amputation; diabetes mellitus was assigned with a significant higher risk for amputation. The mean hospitalization was 32 days, including 8 days on intensive care unit. Of the discovered bacteria 93% were sensitive to the initial antibiotic treatment with Ampicillin, Clindamycin and Clont. CONCLUSION Surgical therapy is indicated if necrotizing fasciitis is suspected. Diabetes mellitus was a clinical predictor of limb amputation in patients with necrotizing fasciitis in our cohort. Aminopenicillin ± sulbactam in combination with clindamycin and/or metronidazole is recommended as initial calculated antibiotic treatment.
Collapse
Affiliation(s)
- M Leiblein
- Department of Trauma, Hand, and Reconstructive Surgery, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
| | - I Marzi
- Department of Trauma, Hand, and Reconstructive Surgery, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - A L Sander
- Department of Trauma, Hand, and Reconstructive Surgery, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - J H Barker
- Experimental Trauma and Orthopedic Surgery, Frankfurt Initiative for Regenerative Medicine, Goethe-Universität, Friedrichsheim gGmbH, 60528, Frankfurt/Main, Germany
| | - F Ebert
- Department of Trauma, Hand, and Reconstructive Surgery, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - J Frank
- Department of Trauma, Hand, and Reconstructive Surgery, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| |
Collapse
|
41
|
Frank J, Frey N, Frank D. Editorial commentary: High-sensitive troponin: A new tool for clinical decision-making in valvular heart disease? Trends Cardiovasc Med 2017; 27:334-335. [PMID: 28274655 DOI: 10.1016/j.tcm.2017.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Accepted: 02/03/2017] [Indexed: 10/20/2022]
Affiliation(s)
- Johanne Frank
- Department of Internal Medicine III (Cardiology and Angiology), University Hospital Schleswig-Holstein, Campus Kiel, Germany.
| | - Norbert Frey
- Department of Internal Medicine III (Cardiology and Angiology), University Hospital Schleswig-Holstein, Campus Kiel, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Kiel, Germany.
| | - Derk Frank
- Department of Internal Medicine III (Cardiology and Angiology), University Hospital Schleswig-Holstein, Campus Kiel, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Kiel, Germany.
| |
Collapse
|
42
|
Sander AL, Sommer K, Schäf D, Braun C, Marzi I, Pohlemann T, Frank J. Clinical outcome after alternative treatment of scaphoid fractures and nonunions. Eur J Trauma Emerg Surg 2017; 44:113-118. [PMID: 28243717 DOI: 10.1007/s00068-017-0773-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2016] [Accepted: 02/08/2017] [Indexed: 10/20/2022]
Abstract
PURPOSE Achieving stable fixation of scaphoid fractures and nonunions continues to be a challenge. Compression screw fixation has been the current standard surgical procedure. However, in some cases, bone healing cannot be achieved and requires further revision. Recent series reintroduced volar plating as valid option for stable fixation. The aim of the study was to review clinical outcome of alternative scaphoid treatment. METHODS From 2011 to 2014, nine patients with scaphoid fracture were treated by Headless Compression Screw (HCS) and seven patients with scaphoid nonunion by HCS or volar mini condylar plate with bone graft. The average age was 34.4 years and the average time to follow-up was 19.3 months. From 1996 to 1998, 38 patients with scaphoid nonunion were treated using compression screw (S-group) or volar mini condylar plate (P-group) with bone graft. The average age was 39.6 years and the average time to follow-up was 26.2 months. RESULTS The union rate was 100%. For scaphoid fractures, the mean Modified Mayo Wrist Score (MMWS) was 94.1 and the DASH score 7.4. From 2011 to 2014, the MMWS was 87.9 and the DASH score 7 in scaphoid nonunions. In the period between 1996 and 1998, the MMWS was 67.2 in the P-group and 58.6 in the S-group, and the DASH score 16.8 and 28.2. CONCLUSIONS Our study demonstrated that appropriate application of the HCS was able to produce very satisfactory results in scaphoid fractures and nonunions. In our opinion, however, the method of scaphoid plate osteosynthesis can achieve a higher degree of stability, particularly rotational stability, in case of multifragmentary avascular scaphoid nonunions.
Collapse
Affiliation(s)
- A L Sander
- Department of Trauma, Hand and Reconstructive Surgery, Hospital of the Johann Wolfgang Goethe-University, Frankfurt/Main, Germany. .,Klinik für Unfall-, Hand- und Wiederherstellungschirurgie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany.
| | - K Sommer
- Department of Trauma, Hand and Reconstructive Surgery, Hospital of the Johann Wolfgang Goethe-University, Frankfurt/Main, Germany
| | - D Schäf
- Department of Trauma, Hand and Reconstructive Surgery, Hospital of the Johann Wolfgang Goethe-University, Frankfurt/Main, Germany
| | - C Braun
- Department of Trauma, Hand and Reconstructive Surgery, St.-Antonius-Hospital, Kleve, Germany
| | - I Marzi
- Department of Trauma, Hand and Reconstructive Surgery, Hospital of the Johann Wolfgang Goethe-University, Frankfurt/Main, Germany
| | - T Pohlemann
- Department of Trauma, Hand and Reconstructive Surgery, Saarland University Medical Center, Homburg, Germany
| | - J Frank
- Department of Trauma, Hand and Reconstructive Surgery, Hospital of the Johann Wolfgang Goethe-University, Frankfurt/Main, Germany
| |
Collapse
|
43
|
Rangrez AY, Hoppe P, Kuhn C, Zille E, Frank J, Frey N, Frank D. MicroRNA miR-301a is a novel cardiac regulator of Cofilin-2. PLoS One 2017; 12:e0183901. [PMID: 28886070 PMCID: PMC5590826 DOI: 10.1371/journal.pone.0183901] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2017] [Accepted: 08/10/2017] [Indexed: 12/19/2022] Open
Abstract
Calsarcin-1 deficient mice develop dilated cardiomyopathy (DCM) phenotype in pure C57BL/6 genetic background (Cs1-ko) despite severe contractile dysfunction and robust activation of fetal gene program. Here we performed a microRNA microarray to identify the molecular causes of this cardiac phenotype that revealed the dysregulation of several microRNAs including miR-301a, which was highly downregulated in Cs1-ko mice compared to the wild-type littermates. Cofilin-2 (Cfl2) was identified as one of the potential targets of miR-301a using prediction databases, which we validated by luciferase assay and mutation of predicted binding sites. Furthermore, expression of miR-301a contrastingly regulated Cfl2 expression levels in neonatal rat ventricular cardiomyocytes (NRVCM). Along these lines, Cfl2 was significantly upregulated in Cs1-ko mice, indicating the physiological association between miR-301a and Cfl2 in vivo. Mechanistically, we found that Cfl2 activated serum response factor response element (SRF-RE) driven luciferase activity in neonatal rat cardiomyocytes and in C2C12 cells. Similarly, knockdown of miR301a activated, whereas, its overexpression inhibited the SRF-RE driven luciferase activity, further strengthening physiological interaction between miR-301a and Cfl2. Interestingly, the expression of SRF and its target genes was strikingly increased in Cs1-ko suggesting a possible in vivo correlation between expression levels of Cfl2/miR-301a and SRF activation, which needs to be independently validated. In summary, our data demonstrates that miR-301a regulates Cofilin-2 in vitro in NRVCM, and in vivo in Cs1-ko mice. Our findings provide an additional and important layer of Cfl2 regulation, which we believe has an extended role in cardiac signal transduction and dilated cardiomyopathy presumably due to the reported involvement of Cfl2 in these mechanisms.
Collapse
Affiliation(s)
- Ashraf Yusuf Rangrez
- Department of Internal Medicine III (Cardiology, Angiology, Intensive Care), University Medical Center Kiel, Kiel, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Kiel, Germany
| | - Phillip Hoppe
- Department of Internal Medicine III (Cardiology, Angiology, Intensive Care), University Medical Center Kiel, Kiel, Germany
| | - Christian Kuhn
- Department of Internal Medicine III (Cardiology, Angiology, Intensive Care), University Medical Center Kiel, Kiel, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Kiel, Germany
| | - Elisa Zille
- Department of Internal Medicine III (Cardiology, Angiology, Intensive Care), University Medical Center Kiel, Kiel, Germany
| | - Johanne Frank
- Department of Internal Medicine III (Cardiology, Angiology, Intensive Care), University Medical Center Kiel, Kiel, Germany
| | - Norbert Frey
- Department of Internal Medicine III (Cardiology, Angiology, Intensive Care), University Medical Center Kiel, Kiel, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Kiel, Germany
| | - Derk Frank
- Department of Internal Medicine III (Cardiology, Angiology, Intensive Care), University Medical Center Kiel, Kiel, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Kiel, Germany
- * E-mail:
| |
Collapse
|
44
|
Abstract
The porphyrias comprise a clinically, biochemically, and genetically heterogeneous group of predominantly hereditary metabolic disorders resulting from a dysfunction along the heme biosynthetic pathway. Whereas most variants can manifest with different cutaneous symptoms, some types only reveal life-threatening acute neurovisceral attacks. Therefore, interdisciplinary care of these patients is advisable. In this article, we provide an overview of characteristic clinical and laboratory findings in the various forms of porphyria and a diagnostic algorithm.
Collapse
Affiliation(s)
- V Kürten
- Hautklinik und Europäisches Porphyriezentrum, Universitätsklinikum der Heinrich-Heine-Universität Düsseldorf, Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland
| | - N J Neumann
- Hautklinik und Europäisches Porphyriezentrum, Universitätsklinikum der Heinrich-Heine-Universität Düsseldorf, Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland
| | - J Frank
- Hautklinik und Europäisches Porphyriezentrum, Universitätsklinikum der Heinrich-Heine-Universität Düsseldorf, Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
| |
Collapse
|
45
|
Abstract
Porphyrias comprise a heterogeneous group of predominantly genetically determined metabolic diseases which are due to a dysfunction in heme biosynthesis. Variegate porphyria and hereditary coproporphyria are referred to as neurocutaneous porphyrias because affected patients can develop both cutaneous symptoms on light-exposed body sites and potentially life-threatening acute neurovisceral symptoms, thereby mimicking several other diseases. In this overview, we provide an update on pathogenesis, clinical manifestation, diagnosis, and therapy of these two types of porphyria.
Collapse
Affiliation(s)
- J Frank
- Hautklinik und Europäisches Porphyriezentrum, Universitätsklinikum der Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
| |
Collapse
|
46
|
Ehrhardt M, Frank J, Smola S, Graf N. Simultaneously double infection of oncolytic viruses leads to addition of cell death induction in glioblastoma cell lines. Klin Padiatr 2016. [DOI: 10.1055/s-0036-1593556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
47
|
Doi L, Williams AJ, Frank J. Growth trajectories and their associated risk factors among children in Scotland. Eur J Public Health 2016. [DOI: 10.1093/eurpub/ckw174.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Hanschke N, Kankofer M, Ruda L, Höltershinken M, Meyer U, Frank J, Dänicke S, Rehage J. The effect of conjugated linoleic acid supplements on oxidative and antioxidative status of dairy cows. J Dairy Sci 2016; 99:8090-8102. [PMID: 27497903 DOI: 10.3168/jds.2015-10685] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2015] [Accepted: 06/24/2016] [Indexed: 01/07/2023]
Abstract
Dairy cows develop frequently negative energy balance around parturition and in early lactation, resulting in excessive mobilization of body fat and subsequently in increased risk of ketosis and other diseases. Dietary conjugated linoleic acid (CLA) supplements are used in dairy cows mainly for their depressing effect on milk fat content, but are also proposed to have antioxidative properties. As negative energy balance is associated with oxidative stress, which is also assumed to contribute to disease development, the present study was conducted to examine effects of CLA on oxidative and antioxidative status of lactating dairy cows. German Holstein cows (primiparous n=13, multiparous n=32) were divided into 3 dietary treatment groups receiving 100g/d of control fat supplement, containing 87% stearic acid (CON; n=14), 50g/d of control fat supplement and 50g/d of CLA supplement (CLA 50; n=15), or 100g/d of CLA supplement (CLA 100; n=16). The CLA supplement was lipid-encapsulated and contained 12% of trans-10,cis-12 CLA and cis-9,trans-11 CLA each. Supplementation took place between d1 and 182 postpartum; d 182 until 252 postpartum served as a depletion period. Blood was sampled at d -21, 1, 21, 70, 105, 140, 182, 224, and 252 relative to calving. The antioxidative status was determined using the ferric-reducing ability of plasma, α-tocopherol, α-tocopherol-to-cholesterol mass ratio, and retinol. For determination of oxidative status concentrations of hydroperoxides, thiobarbituric acid-reactive substances (TBARS), N'-formylkynurenine, and bityrosine were measured. Mixed models of fixed and random effects with repeated measures were used to evaluate period 1 (d -21 to 140) and 2 (d182-252) separately. Cows showed increased oxidative stress and lipid peroxidation during the periparturient period in terms of increased serum concentrations of hydroperoxides and TBARS, which decreased throughout lactation. During period 1, the supplemented cows had lower TBARS concentrations, which was not detectable in period 2. The other determined parameters were not affected by CLA supplementation. The obtained results show that dietary CLA supplementation in the chosen dosage, formulation, and application period had a marginal antioxidative effect in terms of lipid peroxidation in lactating dairy cows.
Collapse
Affiliation(s)
- N Hanschke
- Clinic for Cattle, University of Veterinary Medicine, Foundation, 30173, Hannover, Germany.
| | - M Kankofer
- University of Life Sciences, 20-033, Lublin, Poland
| | - L Ruda
- Clinic for Cattle, University of Veterinary Medicine, Foundation, 30173, Hannover, Germany
| | - M Höltershinken
- Clinic for Cattle, University of Veterinary Medicine, Foundation, 30173, Hannover, Germany
| | - U Meyer
- Institute of Animal Nutrition, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 38116, Braunschweig, Germany
| | - J Frank
- Institute of Biological Chemistry and Nutrition, University of Hohenheim, 70599 Stuttgart, Germany
| | - S Dänicke
- Institute of Animal Nutrition, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 38116, Braunschweig, Germany
| | - J Rehage
- Clinic for Cattle, University of Veterinary Medicine, Foundation, 30173, Hannover, Germany
| |
Collapse
|
49
|
Parren LJMT, Munte K, Winnepenninckx V, van Geel M, Steijlen PM, Frank J, van Steensel MAM. Clustered unilateral trichoepitheliomas indicate Type 1 segmental manifestation of multiple familial trichoepithelioma. Clin Exp Dermatol 2016; 41:682-4. [PMID: 27339671 DOI: 10.1111/ced.12856] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/12/2015] [Indexed: 12/31/2022]
Affiliation(s)
- L J M T Parren
- Department of Dermatology, Jeroen Bosch Hospital, Hertogenbosch, The Netherlands. .,Department of Dermatology, Maastricht University Medical Center, Maastricht, The Netherlands. .,GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
| | - K Munte
- Department of Dermatology, Maasstad Hospital, Rotterdam, The Netherlands
| | - V Winnepenninckx
- Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands
| | - M van Geel
- Department of Dermatology, Maastricht University Medical Center, Maastricht, The Netherlands.,GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.,Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands
| | - P M Steijlen
- Department of Dermatology, Maastricht University Medical Center, Maastricht, The Netherlands.,GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands
| | - J Frank
- Department of Dermatology and Skin Cancer Center, Medical Faculty of the Heinrich Heine University, Düsseldorf, Germany
| | - M A M van Steensel
- Institute of Medical Biology, Immunos, Singapore.,Division of Cancer Science, College of Medicine Dentistry and Nursing, Department of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee, UK
| |
Collapse
|
50
|
Schildge J, Frank J, Klar B. Der Stellenwert der bronchoalveolären Lavage bei der Diagnostik der idiopathischen Lungenfibrose – eine Analyse unter Berücksichtigung des Proteingehaltes. Pneumologie 2016; 70:435-41. [DOI: 10.1055/s-0042-107267] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
ZusammenfassungObwohl die bronchoalveoläre Lavage (BAL) bei der Diagnostik interstitieller Lungenkrankheiten (ILK) häufig zum Einsatz kommt, ist ihr Stellenwert insbesondere bei der idiopathischen Lungenfibrose (IPF) wissenschaftlich umstritten. Berücksichtigt werden in der klinischen Routine die Zellverteilungen in der BAL, nichtzelluläre Merkmale der BAL spielen keine Rolle. Die vorliegende Arbeit untersucht mit Hilfe mathematischer Datenmodellierung, in welchem Umfang BAL-Merkmale einen Rückschluss auf die zugrundeliegende ILK zulassen und/oder eine IPF ausschließen können. In die Berechnung einbezogen werden zelluläre Befunde der BAL, daneben der Protein- und Albumin-Gehalt der BAL, die Nikotinanamnese (pack years) und die Spirometrie (IVC, FEV1).Mittels linearer Diskriminanzanalyse und Erstellung von Klassifikationsbäumen wurde die Relevanz der Merkmale von 806 Patienten mit ILK untersucht (183 IPF, 191 kryptogen organisierende Pneumonie, 147 Lungenbeteiligung bei Autoimmunerkrankung, 97 respiratorische Bronchiolitis mit interstitieller Lungenkrankheit, 118 exogen allergische Alveolitis, 41 lymphozytische interstitielle Pneumonie (LIP), 23 nichtspezifische interstitielle Pneumonie (NSIP), 88 Kontrolle).Protein zeigte in der Gesamtgruppe eine enge positive Beziehung zu den Lymphozyten. Bei IPF und NSIP ist diese Korrelation nicht vorhanden. Albumin ist in allen Gruppen eng mit dem Protein korreliert.Die Lymphozyten sind am besten geeignet, die verschiedenen ILK voneinander abzugrenzen. Eine zuverlässige Kalkulation der ILK ist auf dem Boden der untersuchten Faktoren aber nicht möglich, der Klassifikationsfehler betrug zwischen 23,5 % (IPF) und 100 % (LIP, NSIP). Konstellationen, die mit hoher Wahrscheinlichkeit gegen eine IPF sprechen, sind eine Lymphozytose > 34 % oder ein Proteingehalt > 347 mg/l. Gleiches gilt für die Konstellation Lymphozyten > 25 % und Protein > 250 mg/l.Bei ILK können BAL-Befunde die Diagnose eingrenzen, sind aber selten diagnosesichernd. Zum Ausschluss einer IPF kann die BAL aber einen wichtigen Beitrag leisten.
Collapse
Affiliation(s)
- J. Schildge
- Medizin. Klinik, Abt. Pneumologie, St. Vincentius-Kliniken Karlsruhe gAG
| | - J. Frank
- Fakultät für Mathematik, Karlsruher Institut für Technologie (KIT)
| | - B. Klar
- Fakultät für Mathematik, Karlsruher Institut für Technologie (KIT)
| |
Collapse
|